

[Revision log](#)
[Coding Implications](#)

CONCERT GENETIC TESTING ONCOLOGY: SOLID TUMOR MOLECULAR DIAGNOSTICS

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

OVERVIEW

This policy addresses the use of molecular profiling for a known or suspected solid tumor (e.g. broad molecular profiling, including Minimal Residual Disease (MRD) Testing, Tumor Mutational Burden (TMB), cytogenetic / fusion testing, or circulating tumor DNA (ctDNA)).

While the primary goal of this testing is to identify biomarkers that diagnose cancer, or give prognostic and treatment selection information, this testing also has the potential to uncover clinically relevant germline variations that are associated with a hereditary cancer susceptibility syndrome, and other conditions, if confirmed to be present in the germline. Providers should communicate the potential for these incidental findings with their patients prior to somatic mutation profiling.

For additional information see the [Rationale](#) section.

POLICY REFERENCE TABLE

Coding Implications

This clinical policy references Current Procedural Terminology (CPT[®]). CPT is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2024, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are

included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

The tests, CPT codes, and ICD codes referenced in this policy are not comprehensive, and their inclusion does not represent a guarantee of coverage or non-coverage. Please see the [Concert Platform](#) for additional registered tests.

CRITERIA SECTIONS	EXAMPLE TESTS (LABS)	COMMON BILLING CODES	REF
Molecular Profiling Panels			
Tumor-Type Agnostic Solid Tumor Molecular Profiling Panels	FoundationOne CDx - 0037U (Foundation Medicine)	81445, 81455, 81457, 81458, 81459, 0037U, 0048U, 0250U, 0329U, 0334U, 0379U, 0391U, 0473U, 0523U, C00-D49, Z85	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 29
	MSK-IMPACT - 0048U (Memorial Sloan Kettering Medical Center)		
	Oncomap ExTra - 0329U (Exact Sciences)		
	OnkoSight Advanced Solid Tumor NGS Panel (BioReference Labs)		
	Precise Tumor (Myriad)		
	Tempus xT CDx - 0473U (Tempus)		
	Guardant360 TissueNext - 0334U (Guardant)		

	PGDx elio tissue complete - 0250U (Personal Genome Diagnostics, Inc)		
	OmniSeq INSIGHT (Labcorp)		
	Tempus xT with PD-L1 IHC, MMR IHC (Tempus)		
	Solid Tumor Expanded Panel - 0379U (Quest Diagnostics)		
	UW OncoPlex Cancer Gene Panel (University of Washington)		
	Strata Select - 0391U (Strata Oncology)		
	oncoReveal™ CDx - 0523U (Pillar Biosciences, Inc)		
Targeted RNA Fusion Panels for Solid Tumors	Targeted Solid Tumor NGS Fusion Panel (NeoGenomics)	81449, C91, C34, C71, C49, C96	1, 6, 7, 11, 16, 17
Broad RNA Fusion Panels for Solid Tumor	Aventa FusionPlus - 0444U (Aventa Genomics)	81455, 81456, 0444U, C00-C80	
	OnkoSight Advanced Comprehensive Gene Fusion NGS Panel (BioReference Laboratories)		
	Cancer Gene-Fusion Panel (Children's Hospital of Philadelphia - Division of Genomic Diagnostics)		

Colorectal Cancer Focused Molecular Profiling Panels	Colon Cancer Mutation Panel (Ohio State University Molecular Pathology Lab) COLONSEQPlus Panel (MedFusion)	81445, 81457, C18-C20	2
Lung Cancer Focused Molecular Profiling Panels	Oncomine Dx Target Test - 0022U (Thermo Fisher Scientific) OnkoSight Advanced Lung Cancer NGS Panel (BioReference Laboratories) Lung HDPCR - 0478U (Protean BioDiagnostics)	81457, 0022U, 0478U, C34	1
Cutaneous Melanoma Focused Molecular Profiling Panels	MelanomaSeqPlus (Quest Diagnostics) OnkoSight Advanced Melanoma NGS Panel (BioReference Laboratories)	81445, 81457, C43, D03	18
Single Gene Testing of Solid Tumors			
Tumor Specific <i>BRAF</i> Variant Analysis	BRAF Mutation Analysis (NeoGenomics)	81210, C18-C21, C34, C43, C71, C73, C91.4	1, 2, 5, 7, 9, 11, 18, 20, 21, 22, 23
Tumor Specific <i>BRCA1/2</i> Variant Analysis	BRCA1/2 Mutation Analysis, NGS, Tumor (Mayo Clinic Laboratories) BRCA1/2 Mutation Analysis for Tumors (NeoGenomics Laboratories)	81162, 81163, 81164, 81165, 81166, 81167, 81216, C56, C61	4, 5, 8, 24
Tumor Specific <i>EGFR</i> Variant Analysis	EGFR Mutation Analysis by PCR (NeoGenomics)	81235, C34	1

	Laboratories)		
Tumor Specific <i>ESR1</i> Variant Analysis	ESR1 Mutations Analysis, NGS, Tumor (Mayo Clinic Laboratories)	81479, C50	3
Tumor Specific FOLR1 Protein Analysis	FOLR1 Immunohistochemistry Analysis (Labcorp)	88360, C56	4
Tumor Specific <i>IDH1</i> and <i>IDH2</i> Variant Analysis (Solid Tumor)	IDH1/IDH2 Mutation Analysis by PCR (NeoGenomics)	81120, 81121, 0481U, C71, C92, D49.6	7
	IDH1, IDH2, and TERT Mutation Analysis, Next Generation Sequencing, Tumor (IDTRT) - 0481U (Mayo Clinic)		
Tumor Specific <i>KIT</i> Variant Analysis	KIT Mutation Analysis (ProPath) KIT (D816V) Digital PCR in Systemic Mastocytosis (Labcorp)	81272, 81273, C43, C49.A, C92, D47.1, D47.02	18, 19, 26
Tumor Specific <i>KRAS</i> Variant Analysis	KRAS Mutation Analysis by PCR (NeoGenomics)	81275, 81276, C18-21, C34	1, 2, 5, 27
Tumor Specific <i>MGMT</i> Methylation Analysis	MGMT Promoter Methylation - Tumor (Ohio State University Molecular Pathology Laboratory)	81287, C71	7
Tumor Specific <i>MLH1</i> Methylation Analysis	MLH1 Promoter Methylation Analysis (NeoGenomics)	81288, C18-C21, C54.1	2, 28
Tumor Specific Microsatellite Instability (MSI) Analysis	Microsatellite Instability (MSI) by PCR (NeoGenomics Laboratories) Microsatellite Instability	81301, C15-C23, C50, C53, C54.1, C62, C80	3, 4, 5, 8, 9, 10, 12, 20, 22, 23, 27, 29, 30,

	(MSI) (Quest Diagnostics)		31, 32, 33, 34, 36
Tumor Specific <i>NRAS</i> Variant Analysis	NRAS Mutation Analysis (NeoGenomics)	81311, C18-C21	2
Tumor Specific PD-L1 Protein Analysis	PD-L1, IHC with Interpretation (Quest Diagnostics)	88341, 88342, 88360, 88361, C11, C15, C16, C34, C50, C51, C53, C67	1, 3, 9, 22, 31, 33, 35, 40, 43, 44, 45
Tumor Specific <i>PIK3CA</i> Variant Analysis	PIK3CA Mutation Analysis (Quest Diagnostics)	81309, 0155U, C50, C55	3, 33
	PIK3CA Mutation Analysis, theascreen - QIAGEN - 0155U (LabCorp)		
Tumor Mutational Burden (TMB) Testing			
Tumor Mutational Burden (TMB)	Tumor Mutational Burden (MedFusion)	81479, C00-D49, Z85	3, 4, 5, 8, 9, 10, 12, 20, 22, 23, 27, 29, 30, 31, 32, 33, 34, 35, 36
Measurable (Minimal) Residual Disease (MRD) Testing			
Evidence-Based Solid Tumor Minimal Residual Disease (MRD) Testing	Signatera - Residual Disease Test (MRD) - 0340U (Natera)	81479, 0340U, 0422U, C00-D49, Z85	46, 47
	Guardant Reveal (Guardant Health)		
	Guardant360 Response - 0422U (Guardant Health)		
Emerging Evidence Solid Tumor Minimal Residual	Colvera - 0229U (Clinical Genomics Pathology, Inc.)	0229U, 0306U, 0307U, 0486U, 0498U, 0501U, C00-	

<u>Disease (MRD) Testing</u>	Invitae PCM Tissue Profiling and MRD Baseline Assay - 0306U (Invitae)	D49, Z85	
	Invitae PCM MRD Monitoring - 0307U (Invitae)		
	Northstar Response - 0486U (BillionToOne)		
	OptiSeq Colorectal Cancer NGS Panel - 0498U (DiaCarta Inc.)		
	QuantiDNA Colorectal Cancer Triage Test - 0501U (DiaCarta Inc.)		
<u>HPV-Related Solid Tumor Minimal Residual Disease (MRD) Testing</u>	NavDx - 0356U (Naveris)	0356U, C10.9	46, 47
<u>Molecular Profiling Panel Tests via Circulating Tumor DNA (ctDNA)</u>			
<u>Broad Molecular Profiling Panel Tests via Circulating Tumor DNA (ctDNA)</u>	FoundationOne Liquid CDx - 0239U (Foundation Medicine)	81445, 81455, 81462, 81463, 81464, 0239U, 0242U, 0326U, 0409U, 0485U, 0487U, 0499U, 0530U, C15, C16, C18, C25, C34, C61	1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 18, 22, 27, 34, 40
	Guardant360 - 0326U (Guardant Health)		
	Guardant360 CDx - 0242U (Guardant Health)		
	Guardant360 83+ genes (Guardant Health)		
	NeoLAB Solid Tumor Liquid Biopsy (NeoGenomics Laboratories)		

	Tempus xF: Liquid Biopsy Panel of 105 Genes (Tempus)		
	LiquidHALLMARK - 0409U (Lucence Health)		
	Caris Assure - 0485U (Caris Life Sciences)		
	Northstar Select - 0487U (BillionToOne)		
	OptiSeq Dual Cancer Panel Kit - 0499U (DiaCarta, Inc)		
	LiquidHALLMARK - 0530U (Lucence Health, Inc)		
Lung Cancer Focused Panel Tests via Circulating Tumor DNA (ctDNA)	Resolution ctDx Lung - 0179U (Labcorp)	81210, 81235, 81275, 81462, 81479, 0179U, 0388U, C34	1
	OncoBEAM Lung2: EGFR, KRAS, BRAF (Sysmex Inostics, Inc.)		
	InVisionFirst-Lung Liquid Biopsy - 0388U (NeoGenomics)		
	GeneStrat NGS (Biodesix)		
Single Gene Molecular Profiling Tests via Circulating Tumor DNA (ctDNA)			
EGFR Variant Analysis via ctDNA	EGFR ultrasensitive "liquid biopsy" (Brigham and Women's Hospital - Center for Advanced Molecular Diagnostics)	81235, C34	1, 48

<u>BRAF Variant Analysis via ctDNA</u>	Cell-Free DNA BRAF V600, Blood (Mayo Medical Laboratories) BRAF V600E Mutation Detection in Circulating Cell-Free DNA by Digital Droplet PCR (ARUP Laboratories)	81210, C18-C21, C43	2, 5, 18
<u>KRAS Variant Analysis via ctDNA</u>	Cell-Free DNA KRAS 12, 13, 61, 146 Blood (Mayo Medical Laboratories)	81275, 81276, C18-C20	2, 5
<u>PIK3CA Variant Analysis via ctDNA</u>	therascreen PIK3CA RGQ PCR Kit - 0177U (QIAGEN) Cell-Free DNA PIK3CA Test, Blood (Mayo Medical Laboratories)	81309, 0177U, C50	3
<u>Circulating Tumor Cell (CTC) Tests</u>			
<u>AR-V7 Circulating Tumor Cells (CTC) Analysis</u>	AR-V7 (Epic Sciences)	81479, C61	49
<u>Circulating Tumor Cell (CTC) Enumeration</u>	CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) Test - 0337U (Menarini Silicon) CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) Test - 0338U (Menarini Silicon) CELLSEARCH Circulating Melanoma Cell (CMC) Test - 0490U (Menarini Silicon)	0337U, 0338U, 0490U, 0491U, 0492U, C00.0-C96.9	3, 49

	CELLSEARCH ER Circulating Tumor Cell (CTC-ER) Test - 0491U (Menarini Silicon)		
	CELLSEARCH PD-L1 Circulating Tumor Cell (CTC-PDL1) Test - 0492U (Menarini Silicon)		
<u>Cytogenetic Tumor Testing</u>			
<u>Tumor Specific <i>ALK</i> Gene Rearrangement (Qualitative FISH and PCR) Tests</u>	ALK FISH, Non-Small cell Lung Cancer (Labcorp)	88271, 88274, C34, C73	1, 5, 11, 12, 20, 37
<u>Bladder Cancer Diagnostic and Recurrence FISH Tests</u>	UroVysion Bladder Kit (Quest Diagnostics)	88120, 88121, C67, R31.9, Z85, Z85.5	38, 39
<u>Tumor Specific <i>ERBB2</i> (<i>HER2</i>) Deletion/Duplication (IHC, FISH, and CISH)</u>	ERBB2 (HER2/neu) Gene Amplification by FISH with Reflex, Tissue (ARUP Laboratories)	88360, 88377, C08, C15, C16, C18, C19, C20, C50	2, 3, 4, 5, 9, 22, 23, 29, 33, 35, 40, 43
<u><i>NTRK</i> Fusion Analysis Panel</u>	NTRK NGS Fusion Panel (NeoGenomics Laboratories)	81191, 81192, 81193, 81194, C15, C16, C18, C34, C49.9, C50, C51, C53, C54, C73, C80.1, C91	1, 2, 3, 4, 5, 6, 9, 10, 14, 16, 20, 22, 23, 25, 29, 31, 33, 34, 35, 37, 40, 41, 42
<u>Tumor Specific <i>RET</i> Gene Rearrangement Tests (FISH)</u>	RET FISH (NeoGenomics Laboratories)	88271, 88275, 88291, 88374, 88377, C34, C53, C73	1, 2, 3, 5, 9, 20, 22, 35, 40
	Oncology FISH Analysis - RET Rearrangement (Baylor Genetics, LLC)		

<u>Tumor Specific <i>ROS1</i> Gene Rearrangement</u>	FISH ROS1 Rearrangement (Johns Hopkins Medical Institutions-Pathology Laboratory)	88271, 88274, 88342, 88366, C34	1, 5, 37
<u>Cancer Exome and Genome Sequencing</u>			
<u>Cancer Exome and Genome Sequencing</u>	Somatic Whole Genome Sequencing - 0297U (Praxis Genomics)	81415, 81416, 81425, 81426, 0297U, 0036U, C00-D49, Z85	15
	Cancer Whole Exome Sequencing with Transcriptome (Columbia University - Personalized Genomic Medicine)		
	Tempus xE (Tempus AI, Inc)		

RELATED POLICIES

This policy document provides criteria for testing related to molecular analysis of solid tumors. Please refer to:

- ***Oncology Testing: Hematologic Malignancy Molecular Diagnostics*** for criteria related to molecular profiling of a known or suspected blood cancer (e.g. broad molecular profiling, including Minimal Residual Disease (MRD) Testing, Tumor Mutational Burden (TMB), and cytogenetic / fusion testing).
- ***Oncology Testing: Hereditary Cancer*** for criteria related to genetic testing for hereditary cancer predisposition syndromes.
- ***Oncology Testing: Cancer Screening and Surveillance*** for criteria related to screening and biomarker cancer tests.
- ***Oncology Testing: Algorithmic Assays*** for criteria related to gene expression profiling and tumor biomarker tests with algorithmic analyses.

- ***Specialty Testing: Multisystem Genetic Conditions*** for criteria related to diagnostic tests for genetic disorders that affect multiple organ systems (e.g. whole exome and genome sequencing, chromosomal microarray, and multigene panels for broad phenotypes).
- ***General Approach to Laboratory Testing*** for criteria related to molecular testing for solid tumors, including known familial variant testing, that is not specifically discussed in this or another non-general policy.

[back to top](#)

CRITERIA

It is the policy of health plans affiliated with Centene Corporation[®] that the specific genetic testing noted below is **medically necessary** when meeting the related criteria:

MOLECULAR PROFILING PANELS

Tumor-Type Agnostic Solid Tumor Molecular Profiling Panels

- I. Tumor-type agnostic solid tumor molecular profiling panels are considered **medically necessary** when:
 - A. The member/enrollee meets both of the following:
 1. The member/enrollee has a diagnosis of:
 - a) Recurrent, relapsed, refractory, metastatic, or [advanced](#) stages III or IV cancer, **OR**
 - b) Histiocytosis, **OR**
 - c) Non-small cell lung cancer (NSCLC) regardless of stage, **OR**
 - d) Resectable or borderline resectable pancreatic adenocarcinoma, **OR**
 - e) Central nervous system tumor, **AND**
 2. The member/enrollee is seeking further cancer treatment (e.g., therapeutic chemotherapy), **OR**

- B. The member/enrollee meets one of the following:
1. The member/enrollee is being evaluated for a suspected metastatic malignancy of unknown type, **OR**
 2. The member/enrollee is undergoing initial evaluation for a known or suspected gastric cancer, **OR**
 3. The member/enrollee has a diagnosis of uterine neoplasm, **AND**
 - a) The member/enrollee is undergoing initial evaluation, **OR**
 4. The member/enrollee undergoing initial evaluation for a known or suspected gastrointestinal stromal tumor (GIST), **AND**
 - a) The tumor is negative for *KIT* and *PDGFRA* mutations.
- II. Repeat testing via a tumor-type agnostic solid tumor molecular profiling panel is considered **medically necessary** when:
- A. The member/enrollee has progression of:
1. [Advanced](#) or metastatic non-small cell lung cancer (NSCLC), **OR**
 2. [Advanced](#) or metastatic gastric adenocarcinoma, **OR**
 3. Metastatic prostate cancer.
- III. Current evidence does not support tumor-type agnostic solid tumor molecular profiling panels for all other indications.

NOTE: Additional codes representing additional IHC and/or cytogenetics analyses may be billed alongside the PLA or GSP codes.

[view rationale](#)

[back to top](#)

Targeted RNA Fusion Panels for Solid Tumors

- I. Targeted RNA fusion panels for solid tumors with 5-50 genes performed on peripheral blood, bone marrow or solid tumors are considered **medically necessary** when:
- A. The member/enrollee has a diagnosis of, or is undergoing workup for:

1. Glioma, **OR**
 2. Histiocytosis, **OR**
 3. Sarcoma, **OR**
- B. The member/enrollee has a gastrointestinal stromal tumor, **AND**
1. The tumor is negative for *KIT* and *PDGFRA* somatic mutations, **OR**
- C. The member/enrollee has non-small cell lung cancer, **AND**
1. DNA-based NGS tumor profiling was negative for actionable mutations, **OR**
- D. The member/enrollee has a metastatic or [advanced](#) solid tumor, **AND**
1. There is a fusion-targeted therapy with regulatory approval for that cancer type, **OR**
 2. DNA-based panel testing was negative for oncogenic driver mutations.
- II. Current evidence does not support targeted RNA fusion panels for solid tumors with 5-50 genes performed on peripheral blood, bone marrow or solid tumors for all other indications.

[view rationale](#)

[back to top](#)

Broad RNA Fusion Panels for Solid Tumors

- I. Current evidence does not support broad RNA fusion panels tests with 51 or more genes utilizing RNA analysis alone that are performed on solid tumors for all indications.

[view rationale](#)

[back to top](#)

Colorectal Cancer Focused Molecular Profiling Panels

- I. Colorectal cancer focused molecular profiling panels in solid tumors are considered **medically necessary** when:

- A. The member/enrollee has suspected or proven metastatic colorectal cancer, **AND**
 - B. The panel contains, at a minimum, the following genes: *KRAS*, *NRAS*, *BRAF*.
- II. Current evidence does not support colorectal cancer-focused molecular profiling panels for all other indications.

NOTE: If a panel is performed, appropriate panel codes should be used.

[view rationale](#)

[back to top](#)

Lung Cancer Focused Molecular Profiling Panels

- I. Lung cancer focused molecular profiling panels are considered **medically necessary** when:
- A. The member/enrollee has a diagnosis of:
 - 1. [Advanced](#) (stage IIIb or higher) or metastatic lung adenocarcinoma, **OR**
 - 2. [Advanced](#) (stage IIIb or higher) or metastatic large cell lung carcinoma, **OR**
 - 3. [Advanced](#) (stage IIIb or higher) or metastatic squamous cell lung carcinoma, **OR**
 - 4. [Advanced](#) (stage IIIb or higher) or metastatic non-small cell lung cancer (NSCLC) not otherwise specified (NOS), **AND**
 - B. The member/enrollee is seeking further cancer treatment (e.g., therapeutic chemotherapy).
- II. Repeat lung cancer-focused molecular profiling panels are considered **medically necessary** when the member/enrollee has progression on targeted therapy for non-small cell lung cancer.
- III. Current evidence does not support lung cancer-focused molecular profiling panels for all other indications.

NOTE: If a panel is performed, appropriate panel codes should be used.

[view rationale](#)

[back to top](#)

Cutaneous Melanoma Focused Molecular Profiling Panels

- I. Cutaneous melanoma focused molecular profiling panels are considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of one of the following:
 1. Stage III melanoma or higher, **OR**
 2. Recurrent melanoma, **AND**
 - B. The member/enrollee is seeking further cancer treatment (e.g., therapeutic chemotherapy), **AND**
 - C. One of the following:
 1. The member/enrollee has not had previous somatic testing via a multigene cancer panel for the same primary melanoma diagnosis, **OR**
 2. The member/enrollee **has** had previous somatic testing via a multigene cancer panel for a primary melanoma diagnosis, and has a **new** primary melanoma diagnosis for which this testing is being ordered.
- II. Current evidence does not support cutaneous melanoma focused molecular profiling panels for all other indications.

NOTE: If a panel is performed, appropriate panel codes should be used.

[view rationale](#)

[back to top](#)

SINGLE GENE TESTING OF SOLID TUMORS

Tumor Specific *BRAF* Variant Analysis

- I. Tumor specific *BRAF* variant analysis in solid tumors and hematologic malignancies is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of:

1. Suspected or proven metastatic colorectal cancer, **OR**
 2. [Advanced](#) or metastatic non-small-cell lung cancer (NSCLC), **OR**
 3. Stage III or stage IV cutaneous melanoma, **OR**
 4. Indeterminate thyroid nodules requiring biopsy, **OR**
 5. Anaplastic thyroid carcinoma, **OR**
 6. Locally recurrent, [advanced](#) and/or metastatic papillary thyroid cancer, **OR**
 7. Locally recurrent, [advanced](#) and/or metastatic follicular thyroid cancer, **OR**
 8. Locally recurrent, [advanced](#) and/or metastatic Hurthle cell thyroid carcinoma, **OR**
 9. Low-grade glioma or pilocytic astrocytoma, **OR**
 10. Resectable, borderline resectable, or locally [advanced](#)/metastatic pancreatic adenocarcinoma, **OR**
 11. Metastatic small bowel adenocarcinoma, **OR**
 12. Locally advanced, recurrent or metastatic esophageal or esophagogastric junction cancer, **OR**
 13. Locally advanced, recurrent or metastatic gastric cancer, **OR**
- B. The member/enrollee is being evaluated for:
1. Hairy cell leukemia (for individuals without cHCL [classical hairy cell leukemia] immunophenotype), **OR**
 2. Histiocytosis (Langerhans cell histiocytosis or Erdheim-Chester disease).

[view rationale](#)

[back to top](#)

Tumor Specific *BRCA1/2* Variant Analysis

- I. Tumor specific *BRCA1/2* variant analysis in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of:
 - 1. Ovarian, fallopian tube and/or primary peritoneal cancer, **OR**
 - 2. Metastatic prostate cancer, **OR**
 - 3. Pancreatic cancer.

[view rationale](#)

[back to top](#)

Tumor Specific *EGFR* Variant Analysis

- I. Tumor specific *EGFR* variant analysis in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of:
 - 1. Stage IB or higher lung adenocarcinoma, **OR**
 - 2. Stage IB or higher large cell lung carcinoma, **OR**
 - 3. Stage IB or higher squamous cell lung carcinoma, **OR**
 - 4. Stage IB or higher non-small cell lung cancer (NSCLC) not otherwise specified (NOS).

[view rationale](#)

[back to top](#)

Tumor Specific *ESR1* Variant Analysis

- I. Tumor specific *ESR1* variant analysis in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee is one of the following:

1. Premenopausal female (sex assigned at birth) receiving ovarian ablation or suppression, **OR**
 2. Postmenopausal female (sex assigned at birth), **OR**
 3. Adult male (sex assigned at birth), **AND**
- B. The member/enrollee has a diagnosis of ER-positive and *HER2*-negative breast cancer, **AND**
- C. The member/enrollee has disease progression after one or two prior lines of endocrine therapy, including one line containing a *CDK4/6* inhibitor.

[view rationale](#)

[back to top](#)

Tumor Specific *FOLR1* Protein Analysis

- I. Tumor specific *FOLR1* protein expression analysis via immunohistochemistry (IHC) analysis is considered **medically necessary** when:
 - A. The member/enrollee has recurrent, platinum resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

[view rationale](#)

[back to top](#)

Tumor Specific *IDH1* and *IDH2* Variant Analysis (Solid Tumor)

- I. Tumor specific *IDH1* and *IDH2* variant analysis in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of glioma.

[view rationale](#)

[back to top](#)

Tumor Specific *KIT* Variant Analysis

- I. Tumor specific *KIT* variant analysis in solid tumors or hematologic malignancies is considered **medically necessary** when:

- A. The member/enrollee is being evaluated for systemic mastocytosis, **OR**
- B. The member/enrollee has a diagnosis of acute myeloid leukemia (AML), **OR**
- C. The member/enrollee has stage IV cutaneous melanoma, **OR**
- D. The member/enrollee has a suspected or confirmed gastrointestinal stromal tumor (GIST).

[view rationale](#)

[back to top](#)

Tumor Specific *KRAS* Variant Analysis

- I. Tumor specific *KRAS* variant analysis in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has suspected or proven metastatic colorectal cancer, **OR**
 - B. The member/enrollee has advanced or metastatic non-small cell lung cancer, **OR**
 - C. The member/enrollee has pancreatic adenocarcinoma, **OR**
 - D. The member/enrollee has unresectable or metastatic gallbladder cancer, **OR**
 - E. The member/enrollee has unresectable or metastatic intrahepatic or extrahepatic cholangiocarcinoma.

[view rationale](#)

[back to top](#)

Tumor Specific *MGMT* Methylation Analysis

- I. Tumor specific *MGMT* promoter methylation analysis in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of high grade (grade 3 or 4) glioma.

[view rationale](#)

[back to top](#)

Tumor Specific *MLH1* Methylation Analysis

- I. Tumor specific *MLH1* promoter methylation analysis in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of any of the following:
 1. Colorectal cancer, **OR**
 2. Endometrial (uterine) cancer, **AND**
 - B. Previous tumor testing showed loss of *MLH1* on immunohistochemistry analysis.

[view rationale](#)

[back to top](#)

Tumor Specific Microsatellite Instability (MSI) Analysis

- I. Tumor specific microsatellite instability (MSI) analysis in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of any of the following:
 1. Colorectal cancer, **OR**
 2. Endometrial cancer, **OR**
 3. Gastric cancer, **OR**
 4. Esophageal and esophagogastric junction cancer, **OR**
 5. Recurrent, progressive or metastatic cervical carcinoma, **OR**
 6. Testicular cancer with progression after high dose chemotherapy or third-line therapy, **OR**
 7. Unresectable or metastatic gallbladder cancer, **OR**
 8. Unresectable or metastatic intrahepatic or extrahepatic cholangiocarcinoma, **OR**
 9. Recurrent unresectable or metastatic breast cancer, **OR**

- 10. Small bowel adenocarcinoma, **OR**
- 11. Resectable, borderline resectable, or metastatic pancreatic cancer, **OR**
- 12. Metastatic occult primary, **OR**
- 13. Recurrent, progressive or metastatic squamous cell carcinoma of the vulva, **OR**
- 14. Metastatic chondrosarcoma, **OR**
- 15. Metastatic chordoma, **OR**
- 16. [Widely metastatic](#) Ewing sarcoma, **OR**
- 17. Metastatic osteosarcoma, **OR**
- 18. Recurrent or metastatic vaginal cancer, **OR**
- 19. Recurrent ovarian cancer.

[view rationale](#)

[back to top](#)

Tumor Specific *NRAS* Variant Analysis

- I. Tumor specific *NRAS* variant analysis in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has suspected or proven metastatic colorectal cancer.

[view rationale](#)

[back to top](#)

Tumor Specific PD-L1 Protein Analysis

- I. PD-L1 protein expression analysis via immunohistochemistry (IHC) in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of or is in the initial work up stage for:
 - 1. Stage IB or higher lung adenocarcinoma, **OR**

2. Stage IB or higher large cell lung carcinoma, **OR**
3. Stage IB or higher squamous cell lung carcinoma, **OR**
4. Stage IB or higher non-small cell lung cancer (NSCLC) not otherwise specified (NOS), **OR**
5. Locally [advanced](#) or metastatic bladder cancer, **OR**
6. Recurrent, progressive, or metastatic cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma), **OR**
7. Recurrent unresectable or stage IV triple negative breast cancer, **OR**
8. Locally [advanced](#), recurrent or metastatic esophageal and/or esophagogastric junction adenocarcinoma, **OR**
9. Locally [advanced](#), recurrent or metastatic gastric adenocarcinoma, **OR**
10. Recurrent, unresectable, oligometastatic, or metastatic nasopharyngeal cancer, **OR**
11. Recurrent, progressive or metastatic squamous cell vulvar cancer, **OR**
12. Recurrent or metastatic vaginal cancer.

NOTE: PD-L1 protein expression analysis via IHC is often performed as an adjunct component of comprehensive molecular profiling panels for solid tumors

[view rationale](#)

[back to top](#)

Tumor Specific *PIK3CA* Variant Analysis

- I. Tumor specific *PIK3CA* variant analysis in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of recurrent unresectable or stage IV, HR positive, HER2-negative invasive breast cancer, **OR**
 - B. The member/enrollee has a distantly metastatic salivary gland tumor.

[view rationale](#)

[back to top](#)

TUMOR MUTATIONAL BURDEN (TMB) TESTING

Tumor Mutational Burden (TMB)

- I. [Tumor mutational burden](#) (TMB) testing is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of:
 1. Recurrent, relapsed, refractory, metastatic, or [advanced](#) stages III or IV cancer, **AND**
 - B. The member/enrollee has had progression of the cancer following prior treatment, **AND**
 - C. The member/enrollee has no remaining satisfactory treatment options, **AND**
 - D. The member/enrollee does not have central nervous system cancer.

[view rationale](#)

[back to top](#)

MEASURABLE (MINIMAL) RESIDUAL DISEASE (MRD) TESTING

Evidence-Based Solid Tumor Minimal Residual Disease (MRD) Testing

- I. Minimal residual disease (MRD) analysis for solid tumors using cell-free DNA with sufficient evidence of clinical utility and validity is considered **medically necessary** when:
 - A. The identification of recurrent, refractory, or progressive disease will require a change in management, **AND**
 - B. The member/enrollee is not undergoing concurrent molecular laboratory testing for surveillance or monitoring for recurrent, refractory, or progressive disease, **AND**
 - C. The member/enrollee meets one of the following:

1. The member/enrollee is currently being treated for cancer, **AND**
 - a) The test has not previously been done for this cancer diagnosis, **OR**
 - b) There is a clinical suspicion that the molecular profile of the member/enrollee's tumor has changed, **OR**
 2. The member/enrollee is not currently being treated for their cancer, **AND**
 - a) The test has not been done in the past 12 months, **OR**
 - b) There is a clinical suspicion for tumor recurrence, **AND**
- D. The member/enrollee meets one of the following:
1. The member/enrollee is being tested via Guardant360 Response or Guardant Reveal and has one of the following:
 - a) Metastatic colon cancer, **OR**
 - b) Colon cancer at any stage, **AND**
 - (1) The member/enrollee is being monitored for response to immune checkpoint inhibitor therapy, **OR**
 2. The member/enrollee is being tested via Signatera and has one of the following:
 - a) Metastatic colon cancer, **OR**
 - b) Muscle invasive bladder cancer, **OR**
 - c) Ovarian cancer, **OR**
 - d) Neoadjuvant (pre-surgery) breast cancer, **OR**
 - e) Any solid tumor, **AND**
 - (1) The member/enrollee is being monitored for response to immune checkpoint inhibitor therapy.

- II. Current evidence does not support minimal residual disease (MRD) analysis with sufficient evidence of clinical utility and validity using solid tumor tissue for all other indications where clinical utility and validity have not been demonstrated.

[view rationale](#)

[back to top](#)

Emerging Evidence Solid Tumor Minimal Residual Disease (MRD) Testing

- I. Current evidence does not support minimal residual disease (MRD) analysis with insufficient evidence of clinical validity using solid tumor tissue.

[view rationale](#)

[back to top](#)

HPV-Related Solid Tumor Minimal Residual Disease (MRD) Testing

- I. Minimal residual disease (MRD) analysis for HPV-related head and neck cancers using cell-free DNA is **medically necessary** when:
- A. The member/enrollee has a personal history of HPV-driven oropharyngeal cancer, **AND**
 - B. The identification of recurrence or progression of disease will require a change in management, **AND**
 - C. The member/enrollee is not undergoing concurrent surveillance or monitoring for recurrence or progression by any other method, **AND**
 - D. The member/enrollee meets one of the following:
 - 1. The member/enrollee is currently being treated for HPV-driven oropharyngeal cancer, **AND**
 - a) The test has not previously been done for this episode of cancer, **OR**
 - 2. The member/enrollee is not currently being treated for HPV-driven oropharyngeal cancer, **AND**

- a) The test has not been done in the past 12 months.
- II. Current evidence does not support minimal residual disease (MRD) analysis for HPV-related head and neck cancers using cell-free DNA for all other indications.

[view rationale](#)

[back to top](#)

MOLECULAR PROFILING PANEL TESTS VIA CIRCULATING TUMOR DNA (CTDNA)

Broad Molecular Profiling Panel Tests via Circulating Tumor DNA (ctDNA)

- I. Broad molecular profiling panel tests via [circulating tumor DNA \(ctDNA\)](#) (liquid biopsy) are considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis, progression, or recurrence of one of the following:
 - 1. Metastatic lung adenocarcinoma, **OR**
 - 2. Metastatic large cell lung carcinoma, **OR**
 - 3. Metastatic squamous cell lung carcinoma, **OR**
 - 4. Metastatic non-small cell lung cancer (NSCLC) not otherwise specified (NOS), **OR**
 - 5. Locally [advanced](#)/metastatic pancreatic adenocarcinoma, **OR**
 - 6. Metastatic or [advanced](#) gastric cancer, **OR**
 - 7. Metastatic or [advanced](#) esophageal or esophagogastric junction cancer, **OR**
 - 8. Metastatic prostate cancer, **OR**
 - 9. Stage III or higher cutaneous melanoma, **OR**
 - 10. Metastatic colorectal cancer, **OR**

11. Locally [advanced](#) or metastatic ampullary adenocarcinoma, **OR**
 12. Persistent or recurrent cervical cancer, **OR**
 13. Unresectable or metastatic biliary tract cancer, **OR**
 14. Suspected or confirmed histiocytic neoplasm, **OR**
 15. Locoregional unresectable or metastatic extrapulmonary poorly differentiated neuroendocrine carcinoma, **OR**
 16. Locoregional unresectable or metastatic large or small cell neuroendocrine carcinoma, **OR**
 17. Locoregional unresectable or metastatic mixed neuroendocrine-non-neuroendocrine neoplasm, **OR**
 18. Suspected metastatic malignancy of unknown primary with initial determination of histology, **OR**
 19. Recurrent ovarian, fallopian tube or primary peritoneal cancer, **OR**
 20. Recurrent or stage IV breast cancer, **AND**
- B. If a broad molecular profiling panel test via [circulating tumor DNA \(ctDNA\)](#) is being performed simultaneously with solid tumor tissue testing, the member/enrollee must have one of the following diagnoses:
1. Lung adenocarcinoma, **OR**
 2. Large cell lung carcinoma, **OR**
 3. Squamous cell lung carcinoma, **OR**
 4. Non-small cell lung cancer (NSCLC) not otherwise specified (NOS).
- II. Current evidence does not support broad molecular profiling panel tests via [circulating tumor DNA \(ctDNA\)](#) for all other indications, including being performed simultaneously with solid tumor tissue testing for tumor types other than those described above.

[view rationale](#)

[back to top](#)

Lung Cancer Focused Panel Tests via Circulating Tumor DNA (ctDNA)

- I. Lung cancer focused panel tests via [circulating tumor DNA \(ctDNA\)](#) are considered **medically necessary** when:
 - A. The member/enrollee has a new diagnosis or progression of any of the following:
 1. [Advanced](#) or metastatic lung adenocarcinoma, **OR**
 2. [Advanced](#) or metastatic large cell lung carcinoma, **OR**
 3. [Advanced](#) or metastatic squamous cell lung carcinoma, **OR**
 4. [Advanced](#) or metastatic non-small cell lung cancer (NSCLC) not otherwise specified (NOS).
- II. Current evidence does not support lung cancer focused panel tests via [circulating tumor DNA \(ctDNA\)](#) for all other indications.

[view rationale](#)

[back to top](#)

SINGLE GENE MOLECULAR PROFILING TESTS VIA CIRCULATING TUMOR DNA (CTDNA)

EGFR Variant Analysis via ctDNA

- I. *EGFR* variant analysis via [circulating tumor DNA \(ctDNA\)](#) is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of any of the following:
 1. [Advanced](#) or metastatic lung adenocarcinoma, **OR**
 2. [Advanced](#) or metastatic large cell lung carcinoma, **OR**
 3. [Advanced](#) or metastatic squamous cell lung carcinoma, **OR**
 4. [Advanced](#) or metastatic non-small cell lung cancer (NSCLC) not otherwise specified (NOS).

- II. Current evidence does not support *EGFR* variant analysis via [circulating tumor DNA \(ctDNA\)](#) for all other indications.

[view rationale](#)

[back to top](#)

***BRAF* Variant Analysis via ctDNA**

- I. *BRAF* variant analysis via [circulating tumor DNA \(ctDNA\)](#) is considered **medically necessary** when:
- A. The member/enrollee meets one of the following:
 - 1. The member/enrollee has metastatic colorectal cancer, **OR**
 - 2. The member/enrollee has stage III or higher cutaneous melanoma, **AND**
 - a) Is being considered for adjuvant or other systemic therapy, **OR**
 - 3. The member/enrollee has locally [advanced](#) or metastatic pancreatic adenocarcinoma, **AND**
 - a) Is being considered for anticancer therapy.
- II. Current evidence does not support *BRAF* variant analysis via [circulating tumor DNA \(ctDNA\)](#) is considered **investigational** for all other indications.

[view rationale](#)

[back to top](#)

***KRAS* Variant Analysis via ctDNA**

- I. *KRAS* variant analysis via [circulating tumor DNA \(ctDNA\)](#) is considered **medically necessary** when:
- A. The member/enrollee has metastatic colorectal cancer, **OR**
 - B. The member/enrollee has locally [advanced](#) or metastatic pancreatic adenocarcinoma.
- II. Current evidence does not support *KRAS* variant analysis via [circulating tumor DNA \(ctDNA\)](#) for all other indications.

[view rationale](#)

[back to top](#)

***PIK3CA* Variant Analysis via ctDNA**

- I. *PIK3CA* variant analysis via [circulating tumor DNA \(ctDNA\)](#) is considered **medically necessary** when:
 - A. The member/enrollee has recurrent unresectable, or stage IV hormone receptor-positive/HER2-negative breast cancer, **AND**
 - B. The member/enrollee is considering treatment with alpelisib plus fulvestrant, or capivasertib plus fulvestrant, **AND**
 - C. The member/enrollee has had progression on at least one line of therapy.
- II. Current evidence does not support *PIK3CA* variant analysis via [circulating tumor DNA \(ctDNA\)](#) for all other indications.

[view rationale](#)

[back to top](#)

CIRCULATING TUMOR CELL (CTC) TESTS

AR-V7 Circulating Tumor Cells (CTC) Analysis

- I. AR-V7 [circulating tumor cells \(CTC\)](#) analysis is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of metastatic castration-resistant prostate cancer, **AND**
 - B. Tissue-based testing is not feasible for the member/enrollee, **AND**
 - C. One of the following:
 1. The test is ordered only once during the current cancer diagnosis, **OR**
 2. The test is being performed on newly metastatic cancer, **OR**
 3. The member/enrollee has signs of clinical, radiological or pathologic disease progression.

- II. Current evidence does not support AR-V7 [circulating tumor cells \(CTC\)](#) for all other indications.

[view rationale](#)

[back to top](#)

Circulating Tumor Cell (CTC) Enumeration

- I. Current evidence does not support [Circulating Tumor Cell \(CTC\)](#) for all indications.

[view rationale](#)

[back to top](#)

CYTOGENETIC TUMOR TESTING

Tumor Specific *ALK* Gene Rearrangement (Qualitative FISH and PCR) Tests

- I. Somatic *ALK* gene rearrangement analysis in solid tumors is considered **medically necessary** when:
- A. The member/enrollee has a diagnosis of or is in the initial work up stage for:
1. Stage IB or higher lung adenocarcinoma, **OR**
 2. Stage IB or higher large cell lung carcinoma, **OR**
 3. Stage IB or higher squamous cell lung carcinoma, **OR**
 4. Stage IB or higher non-small cell lung cancer (NSCLC) not otherwise specified (NOS), **OR**
 5. Anaplastic thyroid carcinoma, **OR**
 6. Locally recurrent, [advanced](#), and/or metastatic papillary thyroid carcinoma, **OR**
 7. Locally recurrent, [advanced](#), and/or metastatic follicular thyroid cancer, **OR**
 8. Locally [advanced](#)/metastatic ampullary adenocarcinoma, **OR**

- 9. Langerhans cell histiocytosis, **OR**
- 10. Erdheim-Chester disease, **OR**
- 11. Pancreatic adenocarcinoma, **OR**
- 12. Pediatric (diagnosed age 18 years or younger) diffuse high grade glioma.

[view rationale](#)

[back to top](#)

Bladder Cancer Diagnostic and Recurrence FISH Tests

- I. Bladder cancer diagnostic and recurrence FISH tests for diagnosing and monitoring bladder cancer are considered **medically necessary** when:
 - A. The member/enrollee has hematuria, **AND**
 - 1. Diagnostic studies have failed to identify the etiology of the hematuria, **AND**
 - 2. A bladder cancer diagnostic and recurrence FISH test has not been ordered more than 1 time in the past 12 months, **OR**
 - B. The member/enrollee has been treated for bladder cancer, **AND**
 - 1. The bladder cancer diagnostic and recurrence FISH tests are ordered with the following frequency:
 - a) No more than 4 bladder tumor marker studies per year for years 1-2 after diagnosis
 - b) No more than 3 bladder tumor marker studies during year 3 after diagnosis
 - c) No more than 2 bladder tumor marker studies during year 4 after diagnosis
 - d) No more than 1 bladder tumor marker studies annually for up to 15 years after diagnosis.

- II. Current evidence does not support bladder cancer diagnostic and recurrence FISH tests for diagnosing and monitoring bladder cancer for all other indications.

[view rationale](#)

[back to top](#)

Tumor Specific *ERBB2* (*HER2*) Deletion/Duplication (IHC, FISH, and CISH)

- I. Somatic *ERBB2* (*HER2*) amplification analysis via in situ hybridization (ISH) (i.e., FISH or CISH) or immunohistochemistry (IHC) in solid tumors is considered **medically necessary** when:
- A. The member/enrollee has any of the following:
1. Recurrent or newly diagnosed stage I-IV invasive breast cancer, **OR**
 2. Inoperable locally [advanced](#), recurrent, or metastatic gastric cancer, **OR**
 3. Suspected or proven metastatic colorectal cancer or appendiceal adenocarcinoma, **OR**
 4. Inoperable locally [advanced](#), recurrent, or metastatic esophageal and/or esophagogastric junction adenocarcinoma, **OR**
 5. Recurrent, unresectable, or metastatic salivary gland tumors, **OR**
 6. Recurrent, [advanced](#), or metastatic cervical carcinoma, **OR**
 7. Serous endometrial carcinoma, **OR**
 8. Endometrial carcinosarcoma, **OR**
 9. p53 abnormal endometrial carcinoma, **OR**
 10. Pancreatic adenocarcinoma, **OR**
 11. Recurrent ovarian/fallopian tube/primary peritoneal cancer, **OR**
 12. Recurrent or metastatic vaginal cancer, **OR**
 13. Stage IIIB or higher muscle invasive bladder cancer, **OR**

14. Metastatic small bowel adenocarcinoma.

[view rationale](#)

[back to top](#)

***NTRK* Fusion Analysis Panel**

- I. *NTRK* 1/2/3 fusion analysis panel via fluorescent in situ hybridization (FISH) or immunohistochemistry (IHC) in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee is undergoing initial diagnostic workup for or has a diagnosis of:
 1. [Advanced](#), progressive, or metastatic solid tumor, **OR**
 2. Cancer for which surgical resection is not possible, **OR**
 3. Unknown primary cancers, **OR**
 - B. The member/enrollee has a diagnosis of any of the following cancers at any stage:
 1. Cervical sarcoma, **OR**
 2. Anaplastic thyroid carcinoma, **OR**
 3. Acute lymphoblastic leukemia (ALL), **OR**
 4. Pediatric (diagnosed age 18 years or younger) diffuse high grade glioma.

[view rationale](#)

[back to top](#)

Tumor Specific *RET* Gene Rearrangement Tests (FISH)

- I. Tumor specific *RET* gene rearrangement testing via fluorescent in situ hybridization (FISH) in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of:
 1. Recurrent, persistent locoregional, or metastatic medullary thyroid cancer, **AND**

- a) Germline testing for *RET* mutations is negative or has not been done, **OR**
2. Anaplastic thyroid carcinoma, **OR**
 3. Locally recurrent, [advanced](#) and/or metastatic papillary thyroid carcinoma, **OR**
 4. Locally recurrent, [advanced](#) and/or metastatic follicular thyroid carcinoma, **OR**
 5. Locally recurrent, [advanced](#) and/or metastatic oncocytic carcinoma (formerly called Hurthle cell carcinoma), **OR**
 6. [Advanced](#) or metastatic adenocarcinoma of the lung, **OR**
 7. [Advanced](#) or metastatic large cell cancer of the lung, **OR**
 8. [Advanced](#) or metastatic non-small cell cancer of the lung, not otherwise specified, **OR**
 9. Locally [advanced](#) or metastatic squamous cell carcinoma of the cervix, **OR**
 10. Locally [advanced](#) or metastatic adenocarcinoma of the cervix, **OR**
 11. Locally [advanced](#) or metastatic adenosquamous carcinoma of the cervix, **OR**
 12. Recurrent unresectable or stage IV breast cancer, **OR**
 13. Suspected or confirmed metastatic colon cancer, **OR**
 14. Pancreatic adenocarcinoma, **OR**
 15. Locally [advanced](#), recurrent or metastatic esophageal or esophagogastric junction cancer, **OR**
 16. Locally [advanced](#), recurrent or metastatic gastric cancer, **OR**
 17. Recurrent or metastatic vaginal cancer.

[view rationale](#)

[back to top](#)

Tumor Specific *ROS1* Gene Rearrangement

- I. Tumor specific *ROS1* gene rearrangement analysis in solid tumors is considered **medically necessary** when:
 - A. The member/enrollee has a diagnosis of:
 1. [Advanced](#) or metastatic lung adenocarcinoma, **OR**
 2. [Advanced](#) or metastatic large cell lung carcinoma, **OR**
 3. [Advanced](#) or metastatic squamous cell lung carcinoma, **OR**
 4. [Advanced](#) or metastatic non-small cell lung cancer (NSCLC) not otherwise specified (NOS), **OR**
 5. Locally [advanced](#) or metastatic ampullary adenocarcinoma, **OR**
 6. Pancreatic adenocarcinoma, **OR**
 7. Pediatric (diagnosed age 18 years or younger) diffuse high-grade glioma.

[view rationale](#)

[back to top](#)

CANCER EXOME AND GENOME SEQUENCING

Cancer Exome and Genome Sequencing

- I. Current evidence does not support Cancer exome and genome sequencing in solid tumors and hematologic malignancies for all indications.

[view rationale](#)

[back to top](#)

RATIONALE

Tumor-Type Agnostic Solid Tumor Molecular Profiling Panels

National Comprehensive Cancer Network (NCCN)

The NCCN guidelines on Breast Cancer (6.2024) recommend comprehensive somatic testing to aid in clinical management of patients with recurrent/stage IV breast cancer (p. BINV-18).

The NCCN guideline on Occult Primary (2.2025) recommends tumor mutation burden (TMB), MSI and MMR testing as part of the initial work up for patients with cancer of unknown primary. The guideline further recommends consideration of somatic tumor profiling to identify actionable genomic aberrations after a histological determination of the tumor has been made (p. OCC-1).

The NCCN guideline on Non-Small Cell Lung Cancer (3.2025) has several recommendations regarding biomarker testing:

- Broad molecular profiling is recommended to be performed for stage IV / advanced or metastatic adenocarcinoma, large cell, or NSCLC not otherwise specified. NCCN also recommends consideration of broad molecular profiling for advanced or metastatic squamous cell carcinoma of the lung (p. NSCL-14, NSCL-15, NSCL-19).
- Generally, it is recommended that broad, panel-based genomic profiling be performed via NGS when feasible. NCCN defines broad molecular profiling as a panel which includes all the following biomarkers in either one assay or several smaller assays: *EGFR*, *ALK*, *KRAS*, *ROS1*, *BRAF*, *NTRK1/2/3*, *MET*ex14 skipping, *RET*, *ERBB2 (HER2)*, and *PD-L1* (p. NSCL-19 and NSCL-H 1 and 2 of 8).
- Repeat somatic genetic testing can be helpful to aid in deciding next therapeutic steps when a patient's tumor shows evidence of progression on targeted therapy. Broad genomic profiling may be the best testing method to ensure all possible therapeutic biomarkers are analyzed (p. NSCL-H 7 of 8).

The NCCN guideline for Colon Cancer (6.2024) recommends all patients with metastatic colorectal cancer have molecular testing which should be done, if possible, via a broad NGS panel to identify rare and actionable alterations including fusions (p. COL-2, COL-B 4 of 10). Testing can be performed on the primary tumor and/or metastases (p. COL-B 4 of 10).

The NCCN guideline for Gastric Cancer (5.2024) recommends consideration of NGS testing during the workup for gastric cancer (p. GAST-1). NGS testing can be considered in place of sequential testing for individual biomarkers if there is limited tissue or traditional biopsy cannot

be done in patients with inoperable locally advanced, recurrent or metastatic adenocarcinoma of the stomach considering an FDA approved therapy (p. GAST-B 5 of 6). The guidelines also recommend that repeat tumor testing can be considered when there is clinical or radiologic evidence for disease progression of advanced gastric cancer (p. GAST-B, 3 of 6).

The NCCN guideline for Ovarian Cancer Including Fallopian Tumor Cancer and Primary Peritoneal Cancer (3.2024) recommends that patients with recurrent disease undergo comprehensive tumor molecular analysis to identify alterations that would be amenable to targeted therapeutics that have tumor specific or tumor-agnostic benefit (p OV-6). These guidelines also recommend that molecular testing be performed on the most recent tumor tissue available (p. OV-B, 1 of 3).

The NCCN guideline for Pancreatic Adenocarcinoma (1.2025) recommends tumor/somatic molecular profiling to identify targetable alterations for patients with locally advanced or metastatic disease and recommends consideration of this testing for patients with resectable or borderline resectable disease who are candidates for systemic therapy. Testing can include but is not limited to fusions (*ALK*, *NRG1*, *NTRK*, *ROS1*, *FGFR2*, *RET*), mutations (*BRAF*, *BRCA1/2*, *KRAS*, *PALB2*), amplifications (*HER2*), MSI, tumor mutational burden and mismatch repair deficiency (p. PANC-1A, PANC-F, 1 of 12).

The NCCN guideline for Prostate Cancer (1.2025) recommends consideration of somatic multigene tumor testing to identify alterations in HRR genes in addition to MSI and TMB testing for patients with metastatic prostate cancer. NCCN recommends consideration of this testing in patients with regional prostate cancer. The guidelines also recommend that repeat tumor profiles can be considered at the time of progression of disease (p. PROS-C, 2 of 2).

The NCCN guideline for Histiocytic Neoplasms (3.2024) recommends molecular mutation profiling in the work-up/evaluation of Langerhans Cell Histiocytosis (LCH), Erdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD) for prognostic and treatment information (p. HIST-C, 1 of 5).

The NCCN guideline for Uterine Neoplasms (2.2025) recommends comprehensive molecular profiling in the initial evaluation of uterine neoplasms, including uterine sarcoma (UTSARC-A1 of 8). This can be done on the initial biopsy or the hysterectomy specimen (p. ENDO-A 2 of 4).

NCCN guidelines for Ampullary Adenocarcinoma (2.2024) recommend somatic molecular profiling to identify uncommon and potentially actionable mutations including fusions, amplifications, MSI, dMMR, and TMB for patients with locally advanced or metastatic disease who are candidates for systemic therapy (p. AMP-6).

NCCN guidelines for Gastrointestinal Stromal Tumors (2.2024) recommend molecular testing for a suspected or confirmed gastrointestinal stromal tumor when systemic therapy is being considered (p. GIST-1). If testing does not show a KIT or PDGFRA mutation, NGS testing is recommended to look for alternative driver mutations that will identify targeted therapy options (p. GIST-B).

NCCN guidelines for Central Nervous System Cancers (3.2024) recommend next-generation sequencing in the pathologic workup of CNS tumors, since there are now multiple prognostic and diagnostic biomarkers that should be tested to aid in treatment decisions (p. BRAIN-E 2 of 9).

Food and Drug Administration (FDA)

The FoundationOne CDx test has been approved by the FDA as a companion diagnostic test for several therapies, including some that are indicated for early stage non-small cell lung cancer diagnoses.

[back to top](#)

Targeted RNA Fusion Panels for Solid Tumors

National Comprehensive Cancer Network (NCCN)

NCCN guidelines for Central Nervous System Cancers (3.2024) recommends RNA sequencing to detect fusions in the following genes: *NTRK* and *BRAF* testing in all gliomas including glioblastoma, *BRAF* for diffuse leptomeningeal glioneuronal tumors, high-grade astrocytoma with piloid features (HGAP), or piloid astrocytoma, and *ZFTA* and *YAP1* in ependymomas. Results of this testing inform diagnosis and treatment options. The preferred method is RNA sequencing or other PCR-based breakpoint methods as FISH is unreliable for *BRAF* fusion detection (p. BRAIN-E, 2, 5-6 of 9; GLIO-A 1 of 9).

NCCN guidelines for Non-Small Cell Lung Cancer (3.2025) recommend consideration of RNA-based NGS testing for patients who don't have identifiable driver oncogenes via broad panel testing to maximize detection of fusion events as fusions involving *ROS1*, *MET*, *NTRK*, and *RET* have better detection using RNA based methods (p. NSCL-H, 2, 4, 5 of 8).

NCCN guidelines for Soft Tissue Sarcoma (4.2024) state that while morphologic diagnosis remains the preferred method of sarcoma diagnosis, molecular genetic testing using NGS based methods including DNA and RNA sequencing is an ancillary approach that can be helpful depending on type of tumor (p. SARC-C, 1-2 of 4). Fusion testing also plays a role in therapy selection (p. SARC-G 1 of 13).

NCCN guidelines for Histiocytic Neoplasms (3.2024) recommends a gene fusion assay in the workup for Langerhans Cell Histiocytosis, (p. LCH-2), Erdheim-Chester Disease, (p. ECD-2) and Rosai-Dorfman Disease (p. RDD-2). RNA-based molecular panels including fusion testing should cover *BRAF*, *ALK*, and *NTRK1* rearrangements.

NCCN guidelines for Gastrointestinal Stromal Tumors (2.2024) state that all GIST without a *KIT* or *PDGFRA* mutation should be tested for alternative driver mutations, specifically *BRAF*, *NF1*, *NTRK*, and *FGFR* fusions, which may be detected by NGS to identify potential targeted treatments (p. GIST-B).

American Society of Clinical Oncology

ASCO wrote a Provisional Clinical Opinion (2022) in which it was stated that:

- In patients with metastatic or advanced solid tumors, fusion testing should be performed if there are fusion-targeted therapies with regulatory approval for that specific disease (strength of recommendation: strong).
- Testing for other fusions is recommended in patients with metastatic or advanced solid tumors if no oncogenic driver alterations are identified on large panel DNA sequencing (strength of recommendation: moderate).

[back to top](#)

Broad RNA Fusion Panels for Solid Tumors

None of the National Comprehensive Cancer Network (NCCN) guidelines currently recommend or address performing broad RNA fusion panels as part of evaluation for solid tumors.

[back to top](#)

Colorectal Cancer Focused Molecular Profiling Panels

National Comprehensive Cancer Network (NCCN)

The NCCN guideline for Colon Cancer (6.2024) recommends all patients with suspected or proven metastatic colorectal cancer have tumor genotyping for *KRAS*, *NRAS*, *BRAF*, preferably as part of an NGS panel (p. COL-B, 4 of 10). This testing can be performed on the primary colorectal cancers and/or the metastasis.

[back to top](#)

Lung Cancer Focused Molecular Profiling Panels

National Comprehensive Cancer Network (NCCN)

The NCCN guideline for Non-Small Cell Lung Cancer (3.2025) recommends molecular testing for patients with advanced or metastatic disease and when feasible, testing should be performed via a broad, panel-based approach, most typically performed by NGS. This can be a single assay or a combination of assays and tiered approaches are also acceptable (p. NSCL-19).

Additionally, patients with stages IB-III A or IIIB[T3,N2] are recommended to have testing for PD-L1, EGFR and ALK if perioperative systemic therapy is being considered (p. NSCL-E, 1 of 6). In some clinical scenarios it is necessary to do rapid testing which can be followed up with broad testing (p. NSCL-H, 1 of 8, NSCL-H 2 of 8).

NCCN discusses re-testing tumor tissue in patients with progression who are receiving targeted therapy. This applies to all molecular targets associated with lung cancer and is warranted given it could aid in treatment decision-making (NSCL-H 7 of 8).

[back to top](#)

Cutaneous Melanoma Focused Molecular Profiling Panels

National Comprehensive Cancer Network (NCCN)

The NCCN guidelines for Cutaneous Melanoma (1.2025) recommend molecular testing of *BRAF* for stage III disease, and *KIT* for stage IV disease, or clinical recurrence (p. ME-6, ME-9, ME-18, ME-18A, ME-C 4 of 8). NCCN recommends consideration of broader genomic profiling especially if the test results might guide future treatment decisions or eligibility for participation in a clinical trial (ME-6A). Single gene or small multigene panels are acceptable (p. ME-C, 3 of 8). Repeat testing using the same approach following recurrent or metastatic disease is unlikely to yield useful results. Additionally, NCCN states the following: “Repeat testing following progression on targeted therapy (*BRAF*- or *KIT*-directed therapy) does not appear to have clinical utility” (p. ME-C 5 of 8).

[back to top](#)

Tumor Specific *BRAF* Variant Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN guidelines for Thyroid Carcinoma (5.2024) recommend molecular diagnostic testing for evaluating FNA results that are suspicious for follicular cell neoplasms or AUS/FLUS (THYR-1). The guideline also recommends that individuals with anaplastic thyroid cancer and/or locally recurrent, advanced and/or metastatic papillary, follicular, or oncocytic carcinoma undergo molecular testing including *BRAF*, *NTRK*, *ALK*, and *RET* (p. ANAP-1, p. PAP-10, p. FOLL-9, p. ONC-9).

The NCCN guideline for Hairy Cell Leukemia (1.2025) recommends molecular testing for *BRAF* V600E as a useful part of diagnostic work-up for individuals that do not have cHCL [classical hairy cell leukemia] immunophenotype (p. HCL-1).

The NCCN guideline for Cutaneous Melanoma (1.2025) recommends *BRAF* mutation testing in patients with stage IIIB or higher cutaneous melanoma if adjuvant therapy or clinical trials are being considered (p. ME-4) and recommends consideration of testing of stage IIIA cutaneous melanoma, especially if *BRAF*-directed therapy is a future treatment option (p. ME-5, ME-5A).

The NCCN guideline on Central Nervous System Cancers (3.2024) recommends *BRAF* fusion and/or mutation testing in patients with gliomas to help characterize the tumor and guide treatment decisions (p. BRAIN-E, 5 of 9).

The NCCN guidelines for Non-Small Cell Lung Cancer (3.2025) recommend molecular testing, including *BRAF* analysis, for advanced or metastatic adenocarcinoma, large cell, NSCLC not otherwise specified, or squamous cell carcinoma and consideration of molecular testing for squamous cell carcinoma of the lung (p. NSCL-19).

The NCCN guidelines for Colon Cancer (6.2024) recommends *BRAF* mutation testing (among other genetic testing) for suspected or proven metastatic adenocarcinoma (p. COL-2).

NCCN guidelines for Histiocytic Neoplasms (3.2024) recommends *BRAF* V600E testing (IHC or PCR) from biopsy tissue during the workup for Langerhans cell histiocytosis or Erdheim-Chester disease (p. LCH-2, ECD-2).

NCCN guidelines for Pancreatic Adenocarcinoma (1.2025) recommends consideration of *BRAF* testing for all stages of pancreatic cancer when systemic therapy is being considered (p. PANC-F, 1 of 12), including locally advanced/metastatic disease (p. PANC-1A).

NCCN guidelines for Small Bowel Adenocarcinoma (2.2025) recommend *BRAF* V600E testing for metastatic adenocarcinoma (p. SBA-5).

NCCN guidelines for Esophageal and Esophagogastric Junction Cancers (5.2024) recommend biomarker testing for patients with locally advanced, recurrent or metastatic esophageal or

esophagogastric junction cancer and lists *BRAF* V600E mutation as a targeted biomarker (p. ESOPH-B, 3 and 5 of 6).

NCCN guidelines for Gastric Cancer (5.2024) recommend biomarker testing for patients with locally advanced, recurrent or metastatic gastric cancer and lists *BRAF* V600E mutation as a targeted biomarker (p. GAST-B, 3 and 5 of 6).

[back to top](#)

Tumor Specific BRCA1/2 Variant Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN guideline on Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer (3.2024) recommends that all patients with ovarian cancer, fallopian tube cancer or primary peritoneal cancer should have somatic testing of *BRCA1* and *BRCA2* if not previously done to inform maintenance therapy (p. OV-1).

The NCCN guideline on Prostate Cancer (1.2025) recommends tumor testing for *BRCA1* and *BRCA2* (among other HRR genes) in patients with metastatic prostate cancer and consideration of testing in patients with regional or castration sensitive metastatic prostate cancer (p. PROS-C, 2 of 2).

The NCCN guideline on Pancreatic Adenocarcinoma (1.2025) recommends molecular profiling of tumor tissue for patients with resectable, borderline resectable, or locally advanced/metastatic disease who are candidates for systemic therapy. Testing can include but not be limited to: fusions (*ALK*, *NRG1*, *NTRK*, *ROS1*, *FGFR2*, and *RET*), mutations (*BRAF*, *BRCA1/2*, *KRAS*, and *PALB2*), etc. (p. PANC-1 and PANC-1A, p. PANC-F, 1 of 12).

American Society of Clinical Oncology (ASCO)

ASCO (2020) published recommendations in an article called “Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer”. The guideline includes a recommendation for somatic *BRCA1* and *BRCA2* tumor testing in women who are negative for germline *BRCA1/2* mutations in order to offer FDA approved treatments (i.e., PARP inhibitors) specific to *BRCA1/2* pathogenic or likely pathogenic variants (p. 1223).

[back to top](#)

Tumor Specific *EGFR* Variant Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN guidelines on Non-Small Cell Lung Cancer (3.2025) recommend that molecular testing for *EGFR* mutations should be performed when neoadjuvant TKI therapy or nivolumab is a consideration for NSCLC stage IB–IIIA, IIIB [T3,N2] (p. NSCL-E, 1 of 6, NSCL-E 2 of 6, and NSCL-H 3 of 8). Testing should also be performed for advanced or metastatic disease specifically for patients with advanced or metastatic adenocarcinoma, large cell, or NSCLC not otherwise specified (p. NSCL-19).

[back to top](#)

Tumor Specific *ESR1* Variant Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN guidelines on Breast Cancer (6.2024) recommend *ESR1* testing for HR-positive/HER2 negative breast cancer in “postmenopausal or premenopausal patients receiving ovarian ablation or suppression or adult males with ER-positive, HER2-negative, *ESR1*-mutated disease after progression on one or two prior lines of endocrine therapy, including one line containing a CDK4/6 inhibitor” (p. BINV-Q 6 of 14). Testing for *ESR1* mutations should occur at progression following the endocrine therapy (p. BINV-Q 6 of 14).

[back to top](#)

Tumor Specific FOLR1 Protein Analysis

National Comprehensive Cancer Network (NCCN)

NCCN guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer (3.2024) recommends FOLR1 testing for recurrent, platinum-resistant disease in order to identify potential benefit from targeted therapeutics that have tumor-specific or tumor-agnostic benefit (p. OV-6, LCOC-7, OV-B 1 of 3).

[back to top](#)

Tumor Specific IDH1 and IDH2 Variant Analysis (Solid Tumor)

National Comprehensive Cancer Network (NCCN)

The NCCN guideline on Central Nervous System Cancers (3.2024) recommends *IDH* mutation testing (*IDH1* and *IDH2*) in the work-up for all gliomas (p. BRAIN-E 2 of 9). Additionally, NCCN lists a preferred systemic treatment option (Vorasidenib) for individuals with astrocytoma who are *IDH*-mutant (p. GLIO-A 4 of 9).

[back to top](#)

Tumor Specific *KIT* Variant Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN guideline on Cutaneous Melanoma (1.2025) recommends testing for *KIT* gene mutations in patients with stage IV melanoma as this could impact treatment options (p. ME-9). Molecular testing should be done to confirm *KIT* IHC results (p. ME-C, 3 of 8). NCCN guidelines for Gastrointestinal Stromal Tumors (2.2024) recommend *KIT* mutation analysis to aid in diagnosis of and treatment selection for a gastrointestinal stromal tumor, especially if tyrosine kinase inhibitors (TKIs) are being considered (p. GIST-1 and GIST-B).

The NCCN guidelines on Acute Myeloid Leukemia (1.2025) recommend molecular testing during the evaluation for AML for genes associated with prognosis or treatment options, including c-*KIT* analysis (p. EVAL-1, EVAL-2A).

The NCCN guidelines for Systemic Mastocytosis (3.2024) recommends that all patients presenting with signs or symptoms of mastocytosis undergo molecular testing for *KIT* mutations (specifically, the *KIT* D816V mutation) (p. SM-1).

[back to top](#)

Tumor Specific *KRAS* Variant Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN guideline on Colon Cancer (6.2024) recommends that all patients with suspected or proven metastatic colorectal cancer have tumor testing for *RAS* (*KRAS* and *NRAS*) and *BRAF* mutations individually or as part of an NGS panel as this can inform treatment. Testing can be done on the primary tumor or the metastasis (p. COL-2 and COL-B 4 of 10).

The NCCN guideline on Non-Small Cell Lung Cancer (3.2025) recommends molecular testing, including *KRAS*, for patients with advanced or metastatic adenocarcinoma, large cell, or NSCLC not otherwise specified and recommends consideration of molecular testing for squamous cell

carcinoma of the lung. Testing should be done via broader molecular profiling but concurrent or sequential testing is acceptable (p. NSCL- 19).

NCCN guidelines for Pancreatic Adenocarcinoma (1.2025) indicate that testing for potentially actionable somatic findings including *KRAS* should be considered for resectable or borderline resectable disease when systemic therapy is being considered (p. PANC-F, 1 of 12) as well as in locally advanced/metastatic disease (p. PANC-1A).

NCCN guidelines for Biliary Tract Cancers (6.2024) recommend molecular testing for *KRAS* variant G12C in unresectable or metastatic biliary tract cancers including gallbladder, intrahepatic cholangiocarcinoma, or extrahepatic cholangiocarcinoma (p. BIL-B, 2 of 8).

[back to top](#)

Tumor Specific *MGMT* Methylation Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN guideline for Central Nervous System Cancers (3.2024) recommends *MGMT* promoter methylation testing for all high-grade gliomas (grade 3 and 4). *MGMT* promoter methylation is used for risk stratification in clinical trials and can be helpful with treatment decisions for older adults (specifically, TMZ treatment in non-methylated *MGMT* glioblastoma is not as beneficial) (p. BRAIN-E, 3 of 9).

[back to top](#)

Tumor Specific *MLH1* Methylation Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN guideline on Colon Cancer (6.2024) recommends *MLH1* promoter methylation in all newly diagnosed colon tumors if *MLH1* is abnormal on immunohistochemistry (IHC) (i.e., there is loss of staining of *MLH1* protein) (p. COL-B 4 of 10).

The NCCN guideline on Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric (1.2025) recommends tumor testing for *MLH1* methylation in patients with colorectal or endometrial (uterine) cancer with tumors that show abnormal *MLH1* IHC. Hypermethylation of the *MLH1* promoter in these tumors has been associated with sporadic cancer, and not Lynch syndrome. If germline testing is done and is negative for Lynch syndrome pathogenic mutations, tumor *MLH1* methylation testing is recommended (p. LS-A 2 of 9).

[back to top](#)

Tumor Specific Microsatellite Instability (MSI) Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN guidelines for Colon Cancer (6.2024) recommend determination of tumor MMR or MSI in all individuals with newly diagnosed colorectal cancer (p. COL-B 4 of 10).

The NCCN guidelines for Uterine Neoplasms (2.2025) recommend MSI (among other studies) for patients undergoing initial evaluation for known or suspected uterine malignancy (p. UN-1, ENDO-A 2 of 4, UTSARC-A 1 of 8).

The NCCN guideline on Gastric Cancer (5.2024) recommends MSI testing for all newly diagnosed gastric cancers (p. GAST-1).

The NCCN guideline on Esophageal and Esophagogastric Junction Cancer (5.2024) recommends MSI by PCR or NGS for all patients with newly diagnosed esophageal and EGJ cancers (p. ESOPH-1).

The NCCN guidelines for Cervical Cancer (1.2025) recommend MSI testing for patients with progressive, recurrent, or metastatic cervical carcinoma (p. CERV-A 1 of 7).

The NCCN guideline for Testicular Cancer (1.2025) recommends MSI testing in individuals with pure seminoma or nonseminoma testicular cancer who have had progression after high-dose chemotherapy or third line therapy (p. SEM-7, NSEM-10).

The NCCN guidelines for Biliary Tract Cancers (6.2024) recommends MSI testing for unresectable or metastatic gallbladder cancer or unresectable or metastatic intrahepatic cholangiocarcinoma or extrahepatic cholangiocarcinoma (p. BIL-B, 2 of 8).

The NCCN guidelines for Breast Cancer (6.2024) recommend MSI testing for patients with recurrent unresectable or metastatic breast cancer considering a targeted therapy (p. BINV-Q, 6 of 14).

The NCCN guidelines for Small Bowel Adenocarcinoma (2.2025) recommend universal MSI testing for all patients with newly diagnosed small bowel adenocarcinoma (p. SBA-B).

The NCCN guidelines for an Occult Primary (2.2025) recommend MSI testing as part of work-up for patients with a suspected metastatic malignancy of unknown or uncertain etiology (p. OCC-1).

The NCCN guidelines for Pancreatic Adenocarcinoma (1.2025) recommend MSI (among other studies) for patients with metastatic pancreatic cancer (p. PANC-1A) or resectable or borderline resectable disease when systemic therapy is being considered (p. PANC-F, 1 of 12).

NCCN guidelines for Vulvar Cancer (4.2024) recommend consideration of MSI testing for recurrent, progressive or metastatic squamous cell carcinoma of the vulva (p. VULVA-A, 2 of 4).

NCCN guidelines for Bone Cancer (1.2025) recommend consideration of testing for TMB and MMR/MSI to inform treatment options for metastatic chondrosarcoma, (p. CHON-4), metastatic chordoma (p. CHOR-3), widely metastatic Ewing sarcoma (p. EW-3), and metastatic osteosarcoma (p. OSTEO-3).

NCCN guidelines for Vaginal Cancer (3.2025) recommend consideration of MSI testing for recurrent or metastatic vaginal cancer (p. VAG-5-6, VAG-A 2 of 2).

NCCN guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer (3.2024) recommend MSI testing as part of the molecular tumor workup for recurrent primary ovarian cancer at any stage (p. OV-6, p. OV-B 1 of 3).

[back to top](#)

Tumor Specific *NRAS* Variant Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN guideline on Colon Cancer (6.2024) recommends that all patients with metastatic colorectal cancer should have tumor testing for *RAS* (*KRAS* and *NRAS*) and *BRAF* mutations individually or as part of an NGS panel. Testing can be done on the primary tumor or the metastasis (p. COL-B 4 of 10).

[back to top](#)

Tumor Specific PD-L1 Protein Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN Gastric Cancer guidelines (5.2024) recommends PD-L1 testing during the workup for documented or suspected metastatic adenocarcinoma (p. GAST-1).

The NCCN Head and Neck Cancers guidelines (2.2025) state recommendations for first line therapy which could include PD-L1 inhibitors for recurrent, unresectable, oligometastatic, or metastatic cancer of the nasopharynx (p. NASO-B 1 of 3).

The NCCN Bladder Cancer guidelines (6.2024) states recommendations for specific therapies for individuals with locally advanced or metastatic (stage IV) bladder cancer, which can include PD-L1 inhibitors (p. BL-G 2 of 7).

The NCCN Vulvar Cancer guidelines (4.2024) recommends consideration of PD-L1 testing for individuals with recurrent, progressive, or metastatic squamous cell carcinoma of the vulva (p. VULVA-A 2 of 4).

The NCCN Esophageal and Esophagogastric Junction Cancers guidelines (5.2024) recommends PD-L1 testing for individuals during the workup phase for documented or suspected metastatic esophageal and esophagogastric junction cancers (p. ESOPH-1).

The NCCN Cervical Cancer guidelines (1.2025) recommends PD-L1 testing for individuals with recurrent, progressive, or metastatic cervical cancer of the following pathologies: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (p. CERV-A 1 of 7).

NCCN Non-Small Cell Lung Cancer guidelines (3.2025) recommend PD-L1 testing in patients with stage IB-IIIA, IIIB [T3, N2] non-small cell lung cancer perioperatively (p. NSCL-E, 1 of 5) or for advanced or metastatic adenocarcinoma, large cell, squamous cell, and NSCLC not otherwise specified (NOS) (p. NSCL-19).

The NCCN Breast Cancer guidelines (6.2024) states recommendations for treatments for recurrent unresectable or stage IV triple negative breast cancer based on PD-L1 tumor status (p. BINV-Q 2 of 14).

NCCN guidelines for Vaginal Cancer (3.2025) recommend consideration of PD-L1 testing for recurrent or metastatic vaginal cancer (p. VAG-5, VAG-6, VAG-A 2 of 2).

Food and Drug Administration (FDA)

The FDA's list of cleared or approved companion diagnostic devices lists several cancer types approved for testing via the immunohistochemistry assay for PD-L1 for the purposes of treatment decision-making. These cancer types include, in part: head and neck squamous cell carcinoma, urothelial carcinoma (PMA number 150013, supplement number S014), and triple negative breast cancer (PMA number 150013, supplement S020).

[back to top](#)

Tumor Specific *PIK3CA* Variant Analysis

National Comprehensive Cancer Network (NCCN)

The NCCN guidelines on Breast Cancer (6.2024) recommends molecular testing for *PIK3CA* mutations in patients with recurrent unresectable or stage IV HR-positive/HER2-negative breast cancers (p. BINV-Q, 6 of 15) to identify candidates for FDA-approved therapies.

The NCCN guidelines for Head and Neck Cancers (2.2025) include *PIK3CA* in a list of recommended NGS profiling biomarker testing that should be done prior to treatment for metastatic salivary gland tumors (p. SALI-4).

[back to top](#)

Tumor Mutational Burden (TMB)

National Comprehensive Cancer Network (NCCN)

The NCCN guidelines for Breast Cancer (6.2024) recommend tumor mutation burden (TMB) testing for patients with recurrent unresectable or stage IV disease for whom pembrolizumab is being considered for treatment (p. BINV-Q, 7 of 15).

The NCCN guidelines for Biliary Tract Cancers (6.2024) recommend tumor mutational burden testing for unresectable or metastatic gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma (p. BIL-B, 2 of 8).

The NCCN guidelines for Occult Primary Cancers (2.2025) recommends tumor mutational burden testing for patients with suspected metastatic malignancy of uncertain pathology (p. OCC-1).

The NCCN guidelines for Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer (3.2024) recommend tumor analysis, including tumor mutational burden, for recurrent ovarian/fallopian tube/primary peritoneal cancer (p. OV-B 1 of 3).

The NCCN guidelines for Pancreatic Adenocarcinoma (1.2025) recommend testing of tumor mutational burden for patients with resectable, borderline resectable, or locally advanced and metastatic pancreatic cancer who are candidates for systemic therapy (p. PANC-1, PANC-1A, PANC-F, 1 of 12).

The NCCN guidelines for Prostate Cancer (1.2025) recommend somatic testing for tumor mutational burden for patients with metastatic castration-resistant prostate cancer (p. PROS-15).

The NCCN guidelines for Testicular Cancer (1.2025) recommend tumor mutational burden testing for patients with pure seminoma or nonseminoma testicular cancer who have experienced disease progression after high-dose chemotherapy or third-line therapy (p. SEM-7, NSEM-10).

The NCCN guidelines for Uterine Neoplasms (2.2025) recommend consideration of tumor mutational burden testing for patients with endometrial cancer (p. ENDO-A 2 of 4). The guidelines also recommend tumor mutational burden testing be done for patients with uterine sarcoma (p. UTSARC-A 1 of 8).

NCCN guidelines for Ampullary Adenocarcinoma (2.2024) recommends consideration of tumor/somatic molecular profiling, including tumor mutational burden, for patients with locally advanced/metastatic disease who are candidates for systemic therapy (p. AMP-3).

NCCN guidelines for Bone Cancer (1.2025) recommend consideration of testing for TMB and MMR/MSI to inform treatment options for metastatic chondrosarcoma, (p. CHON-4), metastatic chordoma (p. CHOR-3), widely metastatic Ewing sarcoma (p. EW-3), and metastatic osteosarcoma (p. OSTEO-3).

NCCN guidelines for Esophageal and Esophagogastric Junction Cancers (5.2024) recommends consideration of molecular testing (IHC, FISH, PCR, NGS) for identification of biomarkers for which targeted therapies are approved. Tumor mutational burden is a biomarker for which testing should be done (p. ESOPH-B, 5 of 6).

NCCN guidelines for Gastric Cancer (5.2024) recommends consideration of genomic profiling, including tumor mutational burden, for individuals with unresectable, locally advanced, recurrent or metastatic gastric cancer (p. GAST-B, 5 of 6 and GAST-F 5 of 20).

NCCN guidelines for Head and Neck Cancers (2.2025) recommends that NGS profiling and other appropriate biomarker testing should be done to assess tumor mutational burden (TMB), among other biomarkers, prior to treatment for metastatic salivary gland tumors (p. SALI-4).

NCCN guidelines for Neuroendocrine and Adrenal Tumors (4.2024) recommends consideration of TMB testing for locally advanced unresectable or metastatic, extra pulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm (p. PDNEC-1A) and recommends consideration of TMB testing for adrenocortical carcinoma (p. AGT-5).

NCCN guidelines for Thyroid Carcinoma (5.2024) recommends consideration of tumor mutational burden for patients with locally recurrent, advanced and/or metastatic papillary (p. PAP-10), follicular (p. FOLL-9) or oncocytic carcinoma (p. ONC-9) that is not amenable to RAI therapy, and for patients with stage IVC anaplastic carcinoma (p. ANAP-3).

NCCN guidelines for Vulvar Cancer (4.2024) recommend consideration of tumor mutational burden (TMB) testing in the pathologic assessment for squamous cell carcinoma of the vulva (p. VULVA-A, 2 of 4).

NCCN guidelines for Small Bowel Adenocarcinoma (2.2025) recommend consideration of tumor mutational burden testing for metastatic adenocarcinoma (p. SBA-5).

NCCN guidelines for Vaginal Cancer (3.2025) recommend consideration of tumor mutational burden testing for recurrent or metastatic squamous cell carcinoma/adenocarcinoma of the vagina to help guide systemic treatment options (p. VAG-D 1 of 2, VAG-A 2 of 2).

Food and Drug Administration (FDA)

Per the FDA label for KEYTRUDA (pembrolizumab) injection, TMB is included as part of the indications and usage for the drug:

“Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥ 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. Limitations of Use: The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.”

[back to top](#)

Evidence-Based Solid Tumor Minimal Residual Disease (MRD) Testing

Centers for Medicare and Medicaid Services

The CMS local coverage determination (LCD) entitled “MoIDX: Minimal Residual Disease Testing for Cancer” states the following regarding the use of minimally invasive molecular DNA and RNA tests that detect minimal residual disease (MRD) in patients with a personal history of cancer:

1. The patient has a personal history of cancer, the type and staging of which is within the intended use of the MRD test;
2. The identification of recurrence or progression of disease within the intended use population of the test is identified in the National Comprehensive Cancer Network

(NCCN) or other established guidelines as a condition that requires a definitive change in patient management;

3. The test is demonstrated to identify molecular recurrence or progression before there is clinical, biological or radiographical evidence of recurrence or progression AND demonstrates sensitivity and specificity of subsequent recurrence or progression comparable with or superior to radiographical or other evidence (as per the standard-of-care for monitoring a given cancer type) of recurrence or progression.

“When the patient is NOT known to have cancer (specifically when there is no clinical, radiographical, or other biological evidence that tumor cells remain post treatment and subsequently the patient is no longer being subjected to therapeutic interventions for cancer), a second kind of test may exist wherein a single timepoint may constitute a single test. In such patients, the frequency of MRD testing is in accordance with national or society guidelines or recommendations.”

From the billing and coding article:

“Intended uses that have met clinical validity (CV) criteria under the policy include: (1) the diagnosis of disease progression, recurrence, or relapse for advanced colorectal (Natera and Guardant), muscle-invasive bladder, ovarian, and (neoadjuvant) breast cancers (Natera)....(3) the monitoring of response to immune-checkpoint inhibitor therapy for colorectal cancer (Guardant) or any solid tumor (Natera). However, the tests listed in the table may have only been approved for one or more (but not necessarily all) of these indications.

“Regarding the use of NGS-based MRD tests (i.e., Signatera) in patients with cancer– The service may be performed once per patient per cancer diagnosis, unless there is clinical evidence of *a priori* change in genetic content.”

Concert Note:

For use of minimal residual disease testing, absent clear, specific and evidence-based guideline recommendations for a particular regimen of testing, a default frequency of once per cancer diagnosis for patients with cancer or once every 12 months for patients without cancer will be adopted.

[back to top](#)

Emerging Evidence Solid Tumor Minimal Residual Disease (MRD) Testing

Tests that have limited established clinical utility or validity as defined in the Concert policy for General Approach to Genetic and Molecular testing do not meet the threshold for coverage. Evidence for validity may include a Technology Assessment conducted by an independent third party (e.g. MolDx Tech, ECRI, Optum Genomic) and/or evidence-based guidelines published by professional societies. Such evidence was not identified for the tests referenced by this policy.

[back to top](#)

HPV-Related Solid Tumor Minimal Residual Disease (MRD) Testing

Centers for Medicare and Medicaid Services

The CMS local coverage determination (LCD) entitled “MolDX: Minimal Residual Disease Testing for Cancer” states the following regarding the necessity of minimally invasive molecular DNA and RNA tests that detect minimal residual disease (MRD) in patients with a personal history of cancer:

- The patient has a personal history of cancer, the type and staging of which is within the intended use of the MRD test;
- The identification of recurrence or progression of disease within the intended use population of the test is identified in the National Comprehensive Cancer Network (NCCN) or other established guidelines as a condition that requires a definitive change in patient management;
- The test is demonstrated to identify molecular recurrence or progression before there is clinical, biological or radiographical evidence of recurrence or progression AND demonstrates sensitivity and specificity of subsequent recurrence or progression comparable with or superior to radiographical or other evidence (as per the standard-of-care for monitoring a given cancer type) of recurrence or progression;

When the patient is NOT known to have cancer (specifically when there is no clinical, radiographical, or other biological evidence that tumor cells remain post treatment and subsequently the patient is no longer being subjected to therapeutic interventions for cancer), a second kind of test may exist wherein a single timepoint may constitute a single test. In such patients, the frequency of MRD testing is in accordance with national or society guidelines or recommendations.”

From the billing and coding article:

“Intended uses that have met clinical validity (CV) criteria under the policy include: ... (2) the diagnosis of disease recurrence or relapse for advanced breast (RaDaR) and HPV-driven oropharyngeal cancer (Naveris).... However, the tests listed in the table may have only been approved for one or more (but not necessarily all) of these indications.”

Concert Note

For use of minimal residual disease testing, absent clear, specific and evidence-based guideline recommendations for a particular regimen of testing, a default frequency of once per cancer diagnosis for patients with cancer or once every 12 months for patients without cancer will be adopted.

[back to top](#)

Broad Molecular Profiling Panel Tests via Circulating Tumor DNA (ctDNA)

National Comprehensive Cancer Network (NCCN)

NCCN Prostate Cancer guidelines (1.2025) recommend evaluating tumor for mutations in homologous recombination DNA repair genes (such as *BRCA1*, *BRCA2*, *ATM*, *PALB2*, *FANCA*, *RAD51D*, *CHEK2*, and *CDK12*) in individuals with metastatic prostate cancer. In addition, MSI evaluation is recommended for metastatic prostate cancer. Plasma circulating tumor (ctDNA) assay is an option if biopsy is not able to be performed (PROS-C, 2 of 2).

NCCN Gastric Cancer guidelines (5.2024) recommend consideration of a liquid biopsy based comprehensive genomic profiling assay in patients who have metastatic or advanced gastric cancer who may be unable to safely undergo a traditional biopsy (p. GAST-B 5 of 6).

NCCN Pancreatic Adenocarcinoma guidelines (1.2025) recommend tumor molecular profiling for patients with locally advanced, metastatic disease, recurrence after resection, or disease progression if anti-cancer treatment is being considered. While testing of tumor tissue is preferred, cell-free DNA testing can be considered if tumor tissue testing is not feasible (p. PANC-1, PANC-1A, PANC-5, PANC-9, PANC-10, PANC-11).

NCCN Esophageal and Esophagogastric Junction Cancers guidelines (5.2024) recommend consideration of a liquid biopsy based comprehensive genomic profiling assay in patients who have metastatic or advanced cancer who may be unable to safely undergo a traditional biopsy (p. ESOPH-B 5 of 6).

NCCN Colon Cancer guidelines (6.2024) recommend broad molecular profiling for detection of mutations in *RAS*, *BRAF* and other genes along with *HER2* amplifications and MSI, for patients with suspected or proven metastatic adenocarcinoma and can be done on tissue or blood (p. COL-2). NCCN recommends consideration of repeat testing after targeted therapy to guide future treatment decisions (p. COL-B, 4 of 10).

NCCN Non-Small Cell Lung Cancer guidelines (3.2025) recommend broad-based molecular profiling using ctDNA only when disease is advanced or metastatic adenocarcinoma, large cell, or NSCLC not otherwise specified (NOS). NCCN also recommends consideration of broad molecular profiling for advanced or metastatic squamous cell carcinoma (p. NSCL-19). Per NCCN, “[c]omplete genotyping for *EGFR*, *KRAS*, *ALK*, *ROS1*, *BRAF*, *NTRK1/2/3*, *MET*, *RET*, and *ERBB2* (*HER2*) via biopsy and/or plasma testing” are recommended either on tissue, plasma, or both (p. NSCL-20). Both tissue and ctDNA testing have false negative rates and NCCN recommends consideration of complementary testing to increase the likelihood of mutation detection and reduce time to results (p. NSCL-19, NSCL-H, 8 of 8).

NCCN Cutaneous Melanoma guidelines (1.2025) support the use of cell-free circulating tumor DNA (ctDNA) if tumor tissue is unavailable (p. ME-C 3 of 8). In individuals with initial presentation in stage IV disease, broad genomic profiling using larger NGS panels is recommended if feasible, “especially if the test results might guide future treatment decisions or eligibility for participation in a clinical trial” (ME-C 4 of 8). If *BRAF* single-gene testing was already done and was negative, NCCN recommends consideration of a larger profiling panel to identify other potential biomarkers (p. ME-C 4 of 8).

NCCN Ampullary Adenocarcinoma guidelines (2.2024) recommend somatic molecular profiling for patients with locally advanced or metastatic disease when systemic therapy is being considered. Testing on tumor tissue is preferred but cell-free DNA testing can be considered if tumor tissue testing is not feasible (p. AMP-6).

NCCN Cervical Cancer guidelines (1.2025) recommends consideration of comprehensive molecular profiling for cervical cancer that is persistent or recurrent after treatment. If biopsy of the metastatic site is not feasible or if no tissue is available, testing can be done on circulating tumor DNA (p. CERV-11).

NCCN Biliary Tract Cancers guidelines (6.2024) recommend comprehensive molecular profiling for patients with unresectable or metastatic biliary tract cancer who are candidates for when systemic therapy is an option. NCCN recommends consideration of a cell-free DNA test if there is not enough tissue available or repeat biopsy cannot be done (p. BIL-B, 1 of 8).

NCCN Histiocytic Neoplasms guidelines (3.2024) mention molecular testing in the workup for histiocytosis and state that if biopsy is not possible due to location or risk factors, mutational analysis of peripheral blood is an option (p. LCH-2, ECD-2, RDD-2).

NCCN Neuroendocrine and Adrenal Tumors guidelines (4.2024) recommends consideration of tumor molecular profiling for patients with locoregional unresectable/metastatic extrapulmonary poorly differentiated neuroendocrine carcinoma/large or small cell carcinoma/mixed neuroendocrine-non-neuroendocrine neoplasm when systemic therapy is being considered. Testing on tumor tissue is preferred; however, cell-free DNA testing can be considered if tumor tissue testing is not feasible (p. PDNEC-1, PDNEC-1A).

NCCN Occult Primary guidelines (2.2025) recommend consideration of molecular profiling of tumor tissue after an initial determination of histology has been made. Testing on tumor tissue is preferred; however, cell-free DNA testing can be considered if tumor tissue testing is not feasible (p. OCC-1, OCC-1A).

NCCN Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer guidelines (3.2024) recommend somatic testing for *BRCA1/2* and homologous recombination deficiency status for patients at diagnosis and broader molecular testing in the recurrence setting, especially for less common histologies with limited approved treatment options. Testing may be performed on circulating tumor DNA (ctDNA or liquid biopsy) when tissue-based analysis is not clinically feasible (p. OV-B, 1 of 3).

NCCN Breast Cancer guidelines (6.2024) recommend the use of comprehensive somatic profiling for patients with stage IV or recurrent invasive breast cancer to identify candidates for additional targeted therapies. Biomarker testing should be done on at least the first recurrence, and either tissue or plasma based assays can be used (p. BINV-18).

[back to top](#)

Lung Cancer Focused Panel Tests via Circulating Tumor DNA (ctDNA)

National Comprehensive Cancer Network (NCCN)

The NCCN Non-Small Cell Lung Cancer guidelines (3.2025) recommend biomarker testing be performed pre-treatment for patients with clinically confirmed advanced or metastatic disease of the following lung cancer pathologies: adenocarcinoma, large cell, squamous cell carcinoma, and non-small cell lung cancer not otherwise specified (p. NSCL-14, NSCL-15, NSCL-19, NSCL-H 2-7 of 8). Broad NGS panel-based testing is recommended over other modalities and smaller tests

where feasible (NSCL-H, 2 of 8). Tissue-based testing and ctDNA both have high specificity and false negative rates and therefore can be used together to reduce turnaround time and increase the likelihood of finding actionable targets, however ctDNA should not be used outside of advanced or metastatic disease (NSCL-H 8 of 8). In patients who have progressed following targeted therapy, NCCN recommends consideration of biomarker analysis to evaluate possible mechanisms of resistance (p. NSCL-H, 7 of 8).

[back to top](#)

EGFR Variant Analysis via ctDNA

National Comprehensive Cancer Network (NCCN)

The NCCN Non-Small Cell Lung Cancer guidelines (3.2025) recommend biomarker testing for *EGFR* mutations (among others) for patients with advanced or metastatic disease of the following lung cancer pathologies: adenocarcinoma, large cell, squamous cell carcinoma, and non-small cell lung cancer not otherwise specified (p. NSCL-19). These guidelines also specify that ctDNA testing is not typically recommended for clinical settings except those in which the patient has advanced or metastatic disease (p. NSCL-H 8 of 8).

College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology (2018) published a guideline on molecular testing for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors (TKIs) and noted the following recommendations regarding liquid biopsy for activating *EGFR* mutations and a consensus opinion regarding liquid biopsy for the T790M resistance mutation:

- Recommendation: "In some clinical settings in which tissue is limited and/or insufficient for molecular testing, physicians may use a cfDNA [cell-free DNA] assay to identify [activating] *EGFR* mutations" (p. 337).
- Expert Consensus Opinion: "Physicians may use plasma cfDNA methods to identify *EGFR* T790M mutations in lung adenocarcinoma patients with progression or secondary clinical resistance to *EGFR* targeted TKIs; testing of the tumor sample is recommended if the plasma result is negative" (p. 337).
- No recommendation: "There is currently insufficient evidence to support the use of circulating tumor cell molecular analysis for the diagnosis of primary lung

adenocarcinoma, the identification of *EGFR* or other mutations, or the identification of *EGFR* T790M mutations at the time of *EGFR* TKI resistance" (p. 326).

[back to top](#)

***BRAF* Variant Analysis via ctDNA**

National Comprehensive Cancer Network (NCCN)

NCCN Colon Cancer guidelines (6.2024) recommend tumor molecular testing for *KRAS*, *NRAS*, and *BRAF* mutations in all patients with metastatic colorectal cancer. This analysis can be done either individually or as part of an NGS panel. Additionally, it is noted molecular testing can be performed on tissue as a preferred specimen type or blood-based assay. Finally, *KRAS*, *NRAS*, and *BRAF* mutation analysis can be performed on either primary colorectal tumors or on metastases (p. COL-B, 4 of 10).

NCCN Cutaneous Melanoma guidelines (1.2025) recommend *BRAF* mutation testing for patients with cutaneous melanoma of at least stage III who are being considered for *BRAF* directed therapy or clinical trials (p. ME-5A). Additionally, these guidelines state that molecular testing on tumor tissue is preferred, but may be performed on peripheral blood (liquid biopsy) if tumor tissue is not available (p. ME-C 3 of 8).

NCCN Pancreatic Adenocarcinoma guidelines (1.2025) recommend tumor molecular profiling, including *BRAF*, for patients with advanced or metastatic disease who are candidates for systemic therapy. Tumor tissue is the preferred specimen for this testing, but cell-free DNA can be considered if testing on tissue is not feasible (p. PANC-1A).

[back to top](#)

***KRAS* Variant Analysis via ctDNA**

National Comprehensive Cancer Network (NCCN)

NCCN Colon Cancer guidelines (6.2024) recommend tumor molecular testing for *KRAS*, *NRAS*, and *BRAF* mutations in all patients with metastatic colorectal cancer. This analysis can be done individually, although performing it as part of an NGS panel is preferred. Additionally, it is noted molecular testing can be performed on tissue as a preferred specimen type or blood-based assay. Finally, *KRAS*, *NRAS*, and *BRAF* mutation analysis can be performed on either primary colorectal tumors or on metastases (p. COL-B, 4 of 10).

NCCN Pancreatic Adenocarcinoma guidelines (1.2025) recommend tumor molecular profiling, including *KRAS*, for patients with advanced or metastatic disease who are candidates for systemic therapy. Tumor tissue is the preferred specimen for this testing, but cell-free DNA can be considered if testing on tissue is not feasible (p. PANC-1A).

[back to top](#)

***PIK3CA* Variant Analysis via ctDNA**

National Comprehensive Cancer Network (NCCN)

NCCN Breast Cancer guidelines (6.2024) recommend *PIK3CA* mutation testing for patients with hormone receptor positive/HER2 negative recurrent unresectable or stage IV breast cancer to identify candidates for treatment with alpelisib or capivasertib, plus fulvestrant, as a preferred second or subsequent line of therapy. Testing can be done on tumor tissue or ctDNA in peripheral blood (liquid biopsy). If the liquid biopsy is negative, tumor tissue testing is recommended (p. BINV-Q, 6 of 15).

[back to top](#)

AR-V7 Circulating Tumor Cells (CTC) Analysis

Centers for Medicare and Medicaid Services

The CMS local coverage determination (LCD) entitled “MoIDX: Phenotypic Biomarker Detection in Circulating Tumor Cells” includes the following criteria for circulating tumor cells (CTCs):

“The evidence to date supports HER2 testing from CTCs in breast cancer and AR-V7 testing from CTCs in prostate cancer... In prostate cancer, the presence of AR-V7 from CTCs is currently the basis for making treatment decisions regarding taxane versus ARS inhibitor therapy...”.

The LCD continues on:

“Assays that detect biomarkers from CTCs are covered when ALL of the following are met:

- The specific cancer type has an associated biomarker
- At least 1 of the following criteria are met AND there is clear documentation of at least 1 of these in the medical record:
 - The patient’s cancer has not previously been tested for the specific biomarker, OR

- The patient has newly metastatic cancer, and a metastatic lesion has not been tested for the specific biomarker, OR
- The patient demonstrates signs of clinical, radiological or pathologic disease progression, OR
- There is concern for resistance to treatment based on specific and well-established clinical indications
- Tissue-based testing for the specific biomarker is infeasible (e.g., quantity not sufficient or invasive biopsy is medically contraindicated) OR will not provide sufficient information for subsequent medical management (e.g., in cases where human epidermal growth factor receptor 2 (HER2) overexpression is negative in a tissue biopsy but may be positive in the CTCs, due to tumor heterogeneity). There is clear documentation of at least 1 of these reasons for testing in the medical record.
- For a given patient encounter, only 1 test for assessing the biomarker may be performed UNLESS a second test, meeting all the criteria established herein, is reasonable and necessary as an adjunct to the first test.
- Duplicate testing of the same biomarker (from the same sample type and for the same clinical indication) using different methodologies is not covered. For example, testing for androgen receptor splice variant 7 (AR-V7) from CTCs by messenger RNA (mRNA) as well as immunohistochemistry (IHC)-based methodologies, for the same clinical indication, will not be covered.”

[back to top](#)

Circulating Tumor Cell (CTC) Enumeration

National Comprehensive Cancer Network (NCCN)

NCCN Breast Cancer guidelines (6.2024) mention that guidance for clinical use of circulating tumor cells (CTC) in metastatic breast cancer assessment and monitoring is not currently part of the guideline. Studies mentioned showed that enumeration of circulating tumor cells did not have predictive value (p. MS-77).

Centers for Medicare and Medicaid Services

In the CMS local coverage determination (LCD) “MoIDX: Phenotype Biomarker Detection in Circulating Tumor Cells,” the following is included regarding CTC enumeration analysis: “CTC enumeration may be a good prognostic indicator for certain cancers, but studies do not conclusively suggest a clear effect on outcomes resulting from a change in management.”

[back to top](#)

Tumor Specific *ALK* Gene Rearrangement (Qualitative FISH and PCR) Tests

National Comprehensive Cancer Network (NCCN)

The NCCN Thyroid Carcinoma guidelines (5.2024) recommend that individuals with anaplastic thyroid cancer should undergo molecular testing including *ALK* (p. ANAP-1). *ALK* testing is also recommended for locally recurrent, advanced, and/or metastatic papillary thyroid carcinoma (p. PAP-10) and locally recurrent, advanced, and/or metastatic follicular thyroid carcinoma (p. FOLL-9).

NCCN Non-Small Cell Lung Cancer guidelines (3.2025) recommend *ALK* rearrangement testing in patients with Stage IB-IIIa, IIIB [T3,N2] disease perioperatively for consideration of systemic therapy (p. NSCL-E, 1 of 6) as well as for patients with advanced or metastatic adenocarcinoma, large cell, squamous cell, or NSCLC not otherwise specified (NOS) (p. NSCL-19).

NCCN guidelines for Ampullary Adenocarcinoma (2.2024) recommend somatic molecular profiling for patients with locally advanced/metastatic disease if systemic therapy is being considered. Potentially actionable somatic findings include fusions involving the *ALK* gene (p. AMP-3).

NCCN guidelines for Histiocytic Neoplasms (3.2024) recommends molecular testing of a tissue biopsy during the diagnostic workup for Langerhans cell histiocytosis and Erdheim-Chester disease, and suggests RNA based molecular panel including fusion testing for *ALK*; however if *ALK* rearrangement is suspected clinically, or if fusion panel testing is not available, *ALK* immunohistochemistry and FISH studies may be performed (p. LCH-2, ECD-2).

NCCN guidelines for Pancreatic Adenocarcinoma (1.2025) recommend somatic molecular profiling for patients with locally advanced/metastatic disease as well as those with resectable or borderline resectable disease if systemic therapy is being considered. Potentially actionable somatic findings include fusions involving the *ALK* gene (p. PANC-1A).

NCCN guidelines for Pediatric Central Nervous System Cancers (2.2025) recommend broad molecular testing to classify pediatric diffuse high-grade gliomas. This includes detection of fusions involving the *ALK* gene (p. PGLIO-B, 2 of 4).

[back to top](#)

Bladder Cancer Diagnostic and Recurrence FISH Tests

Centers for Medicare and Medicaid Services

The CMS local coverage determination (LCD) entitled “Lab: Bladder/Urothelial Tumor Markers” includes the following utilization guidelines for bladder marker testing.

Regarding the UroVysion Bladder Cancer Kit: “It is used to detect chromosomal abnormalities in voided urine to assist not only in bladder cancer surveillance but also in the initial identification of bladder cancer.”

“Follow-up after initial diagnosis/most recent occurrence and treatment

- Maximum of 4 bladder tumor marker studies per year for years 1-2
- Maximum of 3 bladder tumor marker studies per year for year 3
- Maximum of 2 bladder tumor marker studies for year 4 and
- Maximum of 1 bladder tumor marker studies follow-up annually for up to 15 years.”

“For high risk patients with persistent hematuria and a negative FISH assay following a comprehensive diagnostic (no tumor identified) workup, ONE repeat FISH testing in conjunction with cystoscopy is considered reasonable and necessary within 1 year of the original attempted diagnosis.”

The CMS LCD Reference Article “Billing and Coding: Lab: Bladder/Urothelial Tumor Markers” states the following: “This A/B MAC will only cover bladder tumor marker fluorescence in situ hybridization (FISH) testing services when performed using validated assays. To date, UroVysion Bladder Cancer Kit is the only Federal Drug Administration (FDA) approved assay that is designed to detect aneuploidy for chromosomes 3, 7, 17 and loss of the 9p21 locus via FISH.

Bladder cancer tumor markers performed by any technology, immunoassay, molecular or FISH testing, are not covered for screening of all patients with hematuria.”

[back to top](#)

Tumor Specific *ERBB2* (*HER2*) Deletion/Duplication (IHC, FISH and CISH)

National Comprehensive Cancer Network (NCCN)

NCCN Esophageal and Esophagogastric Junction Cancers guidelines (5.2024) recommend HER2/*ERBB2* testing using FISH or IHC for patients with inoperable locally advanced, recurrent or metastatic adenocarcinoma if trastuzumab is being considered for treatment (p. ESOPH-B, 3 of 6).

NCCN Head and Neck Cancers guidelines (2.2025) recommend HER2/*ERBB2* testing prior to treatment for individuals diagnosed with recurrent, unresectable, or metastatic salivary gland tumors (p. SALI-4).

NCCN Colon Cancer guidelines (6.2024) recommend HER2/*ERBB2* testing during the workup for suspected or proven metastatic colorectal cancer (p. COL-2). These guidelines also recommend consideration of HER2 analysis for metastatic appendiceal adenocarcinoma (p. COL-I 2 of 3).

NCCN Gastric Cancer guidelines (5.2024) recommend HER2/*ERBB2* testing for patients with inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the stomach if trastuzumab is being considered (p. GAST-B, 3 of 6).

NCCN Breast Cancer guidelines (6.2024) recommend HER2/*ERBB2* testing be performed on all patients with newly diagnosed primary or metastatic breast cancer (p. BINV-A 1 of 2).

NCCN Cervical Cancer guidelines (1.2025) recommend HER2 testing for recurrent, advanced or metastatic cervical carcinoma (p. CERV-A 1 of 7).

NCCN Uterine Neoplasms guidelines (2.2025) recommend HER2 IHC with reflex to FISH for all serous and carcinosarcoma endometrial tumors and recommends consideration of HER2 testing for all tumors that have abnormal p53 by IHC (p. ENDO-A, 1 of 4).

NCCN guidelines for Pancreatic Adenocarcinoma (1.2025) recommend consideration of HER2 amplification testing for patients with locally advanced or metastatic disease (p. PANC-5), recurrence after resection (p. PANC-9), and with resectable or borderline resectable disease being considered for neoadjuvant systemic therapy (p. PANC-F, 1 of 12).

NCCN guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer (3.2024) recommend HER2 testing by IHC for recurrent disease after primary treatment (p. OV-6).

NCCN guidelines for Vaginal Cancer (3.2025) recommend consideration of HER2 testing by IHC or FISH for recurrent or metastatic vaginal cancer (p. VAG-5, VAG-6, VAG-A 2 of 2).

NCCN guidelines for Bladder Cancer (6.2024) recommend consideration of IHC for HER2 overexpression for stage IIIB or higher muscle invasive bladder cancer (p. BL-8 through BL-10).

NCCN guidelines for Small Bowel Adenocarcinoma (2.2025) recommend testing for HER2 amplifications for patients with metastatic disease (p. SBA-5).

[back to top](#)

***NTRK* Fusion Analysis Panel**

National Comprehensive Cancer Network (NCCN)

The NCCN Thyroid Carcinoma guidelines (5.2024) recommend that individuals with anaplastic thyroid cancer (p. ANAP-1) or locally recurrent, advanced, and/or metastatic papillary, follicular, and oncocytic carcinoma (formerly called Hurthle cell carcinoma) undergo molecular testing including *NTRK* as part of disease workup (p. PAP-10, p. FOLL-9, p. ONC-9).

The NCCN Colon Cancer Guidelines (6.2024) recommend broad molecular profiling to, including *NTRK*, for patients with suspected or proven metastatic adenocarcinoma (p. COL-2). For individuals who are *NTRK* gene fusion-positive, NCCN lists the following biomarker-directed therapies: entrectinib, larotrectinib, and repotrectinib (p. COL-D 2 of 11).

The NCCN Non-Small Cell Lung Cancer guidelines (3.2025) recommends *NTRK* molecular analysis for patients with advanced or metastatic adenocarcinoma, large cell carcinoma, and NSCLC not otherwise specified (NOS) and recommends consideration of *NTRK* testing for advanced or metastatic squamous cell carcinoma of the lung (p. NSCL-19). For individuals who are *NTRK* gene fusion-positive, NCCN lists the following biomarker-directed therapies: entrectinib, larotrectinib, and repotrectinib (p. NSCL-33).

The NCCN Occult Primary guidelines (2.2025) states that patients with metastatic or unresectable *NTRK* gene fusion positive adenocarcinomas without a known acquired resistance mutation, who have no satisfactory treatment options or who have progressed on treatment can be treated with entrectinib and/or larotrectinib or repotrectinib (p. OCC-B, 8 of 14).

The NCCN Cervical Cancer guidelines (1.2025) recommends *NTRK* fusion analysis for patients with cervical sarcoma (p. CERV-A 1 of 7).

The NCCN Vulvar Cancer guidelines (4.2024) recommends consideration of *NTRK* fusion analysis for recurrent, progressive, or metastatic squamous cell carcinoma of the vulva (p. VULVA-A 2 of 4).

The NCCN Uterine Neoplasms guidelines (2.2025) recommends consideration of *NTRK* fusion analysis for recurrent or metastatic endometrial carcinoma (p. ENDO-A 2 of 4) or metastatic uterine sarcoma (p. UTSARC-A 1 of 8).

The NCCN Breast Cancer guidelines (6.2024) recommend *NTRK* fusion testing for recurrent unresectable or stage IV disease if eligible for larotrectinib, entrectinib or repotrectinib treatment (no known resistance mutation and no satisfactory alternatives or have progressed on treatment) (p. BINV-Q 7 of 14).

The NCCN Gastric Cancer guidelines (5.2024) recommends consideration of comprehensive genomic profiling including *NTRK* fusion analysis for unresectable locally advanced, recurrent, or metastatic gastric cancer (p. GAST-B 5 of 6, GAST-F 5 of 20).

The NCCN Esophageal and Esophagogastric Junction Cancer guidelines (5.2024) recommends consideration of comprehensive genomic profiling including *NTRK* fusion analysis for unresectable, locally advanced, recurrent, or metastatic esophageal cancer (p. ESOPH-B 5 of 6). For individuals who are *NTRK* gene fusion-positive, NCCN lists the following biomarker-directed therapies: entrectinib, larotrectinib, and repotrectinib (p. ESOPH-F 6 of 22).

The NCCN Acute Lymphoblastic Leukemia guidelines (3.2024) and Pediatric Acute Lymphoblastic Leukemia guidelines (2.2025) recommend *NTRK* fusion analysis for acute lymphoblastic leukemia (ALL) for the purposes of risk stratification (p. ALL-3; p. PEDALL-B).

The NCCN Soft Tissue Sarcoma guidelines (4.2024) recommend larotrectinib, entrectinib or repotrectinib for patients with advanced or metastatic disease and *NTRK* gene fusion-positive tumors (p. SARC-G 1 of 13).

The NCCN Neuroendocrine and Adrenal Tumors guidelines (4.2024) recommends consideration of *NTRK* fusion testing for patients with unresectable or metastatic extrapulmonary poorly differentiated neuroendocrine carcinoma/large or small cell carcinoma/mixed neuroendocrine-non-neuroendocrine neoplasm (p. PDNEC-1, PDNEC-1A). For individuals who are *NTRK* gene fusion-positive, NCCN lists the following biomarker-directed therapies: entrectinib, larotrectinib, and repotrectinib (p. NE-H 5 of 9).

The NCCN Head and Neck Cancers guidelines (2.2025) recommend use of NGS profiling and other appropriate biomarker testing to evaluate *NTRK* prior to treatment for metastatic salivary gland tumors (p. SALI-4).

The NCCN Hepatocellular Carcinoma guidelines (2.2024) indicate that larotrectinib, entrectinib, and repotrectinib are options for treatment in patients with *NTRK* gene fusion positive tumors (p. HCC-I, 1 of 2).

The NCCN Ovarian Cancer/Fallopian Tube Cancer/ Primary Peritoneal Cancer guidelines (3.2024) recommend tumor molecular testing including *NTRK* testing for recurrent disease if prior testing for these markers was not done (p. OV-6). For individuals who are *NTRK* gene fusion-positive, NCCN lists the following biomarker-directed therapies: entrectinib, larotrectinib, and repotrectinib (p. OV-C 8 of 12).

The NCCN Small Bowel Adenocarcinoma guidelines (2.2025) recommends larotrectinib and entrectinib as options for subsequent-line treatment of metastatic small bowel adenocarcinoma that is *NTRK* gene fusion positive (p. SBA-D 1 of 7).

The NCCN Pediatric Central Nervous System Cancers guidelines (2.2025) state that broad molecular testing is required for comprehensive classification of pediatric diffuse high-grade gliomas, including NGS with fusion detection for *NTRK1/2/3*, (p. PGLIO-B, 2 of 4).

The NCCN guidelines for Pancreatic Adenocarcinoma (1.2025) recommend testing for potentially actionable somatic findings including *NTRK* fusions for patients with locally advanced/metastatic disease (p. PANC-1 and PANC-1A). In addition, patients with resectable or borderline resectable disease who are considering systemic therapy are recommended to consider testing for somatic findings including *NTRK* fusions (p. PANC-F, 1 of 12). For individuals who are *NTRK* gene fusion-positive, NCCN lists the following biomarker-directed therapies: entrectinib, larotrectinib, and repotrectinib (p. PANC-F 3 of 12).

The NCCN guidelines for Vaginal Cancer (3.2025) recommend consideration of *NTRK* fusion testing for recurrent or metastatic vaginal cancer (p. VAG-5, VAG-6, VAG-A 2 of 2).

The NCCN guidelines for Gastrointestinal Stromal Tumors (2.2024) lists the following biomarker-directed therapies for individuals with unresectable, progressive or metastatic disease: entrectinib, larotrectinib, and repotrectinib (p. GIST-E 1 of 4, GIST-E 2 of 4).

Food and Drug Administration

The FDA label for Augtyro (repotrectinib) includes indications and usage information for the treatment of the following:

- “adult patients with locally advanced or metastatic ROS1-positive nonsmall cell lung cancer (NSCLC) (1.1).
- adult and pediatric patients 12 years of age and older with solid tumors that:
 - have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and
 - are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity.

have progressed following treatment or have no satisfactory alternative therapy.

[back to top](#)

Tumor Specific *RET* Gene Rearrangement Tests (FISH)

National Comprehensive Cancer Network (NCCN)

The NCCN guidelines on Thyroid Carcinoma (5.2024) recommend that patients with recurrent or persistent medullary thyroid carcinoma, or patients with symptomatic disease/progression should have somatic *RET* testing if germline wild type or germline unknown (p. MEDU-6 and MEDU-7). The guideline also recommends that individuals with anaplastic thyroid cancer and/or locally recurrent, advanced, and/or metastatic papillary, follicular, or oncocytic carcinoma that cannot be treated with radioactive iodine should undergo molecular testing including *RET* if not previously done (p. ANAP-3, PAP-10, FOLL-9, ONC-9).

The NCCN guideline on Non-Small Cell Lung Cancer (3.2025) recommends analysis for *RET* gene rearrangements in patients with advanced or metastatic adenocarcinoma of the lung, large cell carcinoma of the lung, or NSCLC not otherwise specified and recommends consideration of *RET* gene testing for patients with advanced or metastatic squamous cell carcinoma of the lung (p. NSCL-19), noting that NGS-based methodology has a high specificity and that RNA-based NGS is preferable to DNA-based NGS for fusion detection (p. NSCL-H, 5 of 8).

The NCCN guideline for Cervical Cancer (1.2025) recommends consideration of *RET* gene fusion testing for patients with locally advanced or metastatic cervical cancer of the following pathologies: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (p. CERV-1 and CERV-A, 1 of 7).

NCCN guidelines for Breast Cancer (6.2024) list *RET* fusion as a biomarker with an FDA approved therapy for any subtype of recurrent unresectable or stage IV disease. Either tumor tissue or blood can be used for detection (p. BINV-Q, 6 of 14).

NCCN guidelines for Colon Cancer (6.2024) recommend broad molecular profiling including *RET* fusion detection as part of the workup for suspected or proven metastatic adenocarcinoma (p. COL-2).

NCCN guidelines for Pancreatic Adenocarcinoma (1.2025) recommends consideration of testing for somatic mutations including *RET* fusions for resectable or borderline resectable disease when systemic therapy is being considered (p. PANC-F, 1 of 12) and recommends this testing for locally advanced/metastatic disease (p. PANC-1 and PANC-1A).

NCCN guidelines for Esophageal and Esophagogastric Junction Cancers (5.2024) recommend consideration of *RET* gene fusion testing for patients with squamous cell carcinoma and locally advanced, recurrent or metastatic esophageal or esophagogastric junction cancer (p. ESOPH-B, 5 of 6, ESOPH-10, ESOPH-19).

NCCN guidelines for Gastric Cancer (5.2024) recommend consideration of *RET* gene fusion testing for patients with locally advanced, recurrent or metastatic gastric cancer (p. GAST-B, 5 of 6).

NCCN guidelines for Vaginal Cancer (3.2025) recommend consideration of *RET* fusion testing for recurrent or metastatic vaginal cancer (p. VAG-6 and VAG-A 2 of 2).

[back to top](#)

Tumor Specific *ROS1* Gene Rearrangement

National Comprehensive Cancer Network (NCCN)

NCCN Non-Small Cell Lung Cancer guidelines (3.2025) recommend *ROS1* rearrangement testing in patients with advanced or metastatic disease of the following lung cancer pathologies: adenocarcinoma, large cell, and NSCLC not otherwise specified (NOS) squamous cell carcinoma of the lung (p. NSCL-19). NCCN guidelines for Ampullary Adenocarcinoma (2.2024) recommend consideration of tumor molecular profiling, including for *ROS1* fusions, for patients with locally advanced or metastatic disease who are considering systemic therapy (p. AMP-3).

NCCN guidelines for Pancreatic Adenocarcinoma (1.2025) recommends consideration of tumor molecular profiling including *ROS1* fusions for patients with resectable or borderline resectable disease (p. PANC-F, 1 of 12) and recommends this testing for locally advanced or metastatic disease (p. PANC-1A).

NCCN guidelines for Pediatric Central Nervous System Cancers (2.2025) state that broad molecular testing is required for comprehensive classification of pediatric diffuse high-grade gliomas, including detection of fusions involving *ROS1* (p. PGLIO-B, 2 of 4).

[back to top](#)

Cancer Exome and Genome Sequencing

National Comprehensive Cancer Network Biomarker Compendium

None of the National Comprehensive Cancer Network (NCCN) guidelines currently recommend or address performing cancer exome and/or genome sequencing as part of evaluation for cancers or tumors.

[back to top](#)

DEFINITIONS

1. **Advanced cancer** (advanced stages or advanced tumor or advanced/metastatic): Cancer that is unlikely to be cured or controlled with treatment. The cancer may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body. Treatment may be given to help shrink the tumor, slow the growth of cancer cells, or relieve symptoms.
2. **Circulating tumor DNA (ctDNA)** is fragmented, tumor-derived DNA circulating in the bloodstream that is not being carried in a cell. ctDNA derives either directly from the tumor or from circulating tumor cells.
3. **Circulating Tumor Cells (CTCs)** are intact cells that have shed into the bloodstream or lymphatic system from a primary tumor or a metastasis site, and are carried around the body by blood circulation.
4. **Tumor mutational burden:** A measurement of mutations carried by tumor cells and is a predictive biomarker that is being studied to evaluate its association with response to immunotherapy.
5. **Widely metastatic:** A cancer for which local control cannot be delivered to all areas of disease (per NCCN guidelines).

[back to top](#)

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy developed.	03/23	03/23
Semi-annual review. Updated title to reflect V1.2024 version. Overview, coding, reference-table, background and references updated. Throughout policy: replaced “coverage criteria” with “criteria. For Overview: removed “also to”. For Policy Reference Table: removed “88275, 88291”; added Tumor Specific RET Gene Rearrangement (FISH) and related content. For Other Related Policies: added “and Molecular”. For Criteria; under Tumor Specific ALK Gene Rearrangement (Qualitative FISH and PCR) Tests: I. removed “88275, 88291”; I.A.1-I.A.4. replaced “Advanced or metastatic” with “Stage IB or higher”; I.A.5. added “OR”; I.A.6. added “Locally recurrent, advanced, and/or metastatic papillary...”; I.A.7. added “Locally recurrent, advanced, and/or metastatic follicular...”; under Tumor Specific BCR/ABL1 Gene Rearrangement (Qualitative FISH and PCR) Tests: I. replaced “Somatic” with “Tumor specific”; I.B.3. replaced “myelogenous” with “myeloid”; added “OR”; I.B.4. added “B-cell lymphoma”; added “Note: Refer to Oncology...”;	10/23	10/23

Reviews, Revisions, and Approvals	Revision Date	Approval Date
under Tumor Specific ERBB2 (HER2) Deletion/Duplication (FISH and CISH): I. added “or immunohistochemistry (IHC)”; I.A.3. removed “synchronous”; under Multiple Myeloma FISH Panel Analysis: removed “88274”; added “88273”; for NTRK Fusion Analysis Panel: removed “Somatic”; added “panel”; added I.A.16. “Unresectable or metastatic...”; under Tumor Specific PD-L1 Protein Analysis: I.A.1-I.A.4. replaced “Advanced or metastatic” with “Stage IB or higher”; added Tumor Specific FOLR1 Protein Analysis and related criteria; under Tumor Specific PML/RARA Gene Rearrangement (Qualitative FISH and PCR): I. added “81315, 81316”; added Tumor Specific RET Gene Rearrangement Tests (FISH) and related criteria. For Background and Rationale: added “ALK testing is also recommended...”; removed “advanced or metastatic disease of lung”; added “Stage IB-IIIA...”; added “NCCN B-cell Lymphoma...”; added “The NCCN Neuroendocrine...”; under Tumor Specific PD-L1 Protein Analysis: removed “advanced or metastatic disease...”; added “stage IB-IIIB...”; added Tumor Specific FOLR1 Protein Analysis and related content; added Tumor Specific <i>RET</i> Gene Rearrangement (FISH) and related content.		
Semi-annual review. Updated title to reflect V2.2024 version. In Tumor Specific <i>ALK</i> Gene Rearrangement (Qualitative FISH and PCR) Tests, minor expansion of criteria to be consistent with guidelines (added several tumor types for coverage). Tumor Specific BCR/ABL Gene Rearrangement (Qualitative FISH and PCR) Tests, moved criteria and combined with BCR/ABL1 criteria in the Solid Tumor and Hematological Malignancies policy to align with the clinical use of these tests. In Tumor Specific <i>ERBB2 (HER2)</i> Deletion/Duplication (FISH and CISH), minor expansion of criteria to be consistent with guidelines (added several tumor types for coverage). In <i>NTRK</i> Fusion Analysis Panel, Minor expansion of criteria to be consistent with guidelines (added several tumor types for coverage). In Tumor Specific FOLR1 Protein Analysis, Clarified ovarian cancer pathology. In Tumor Specific <i>RET</i> Gene Rearrangement Tests (FISH0), minor expansion of criteria to be consistent with guidelines (added several tumor types). In Tumor Specific <i>ROS1</i> Gene Rearrangement, minor expansion of criteria to be consistent with guidelines (added several tumor types for coverage). Minor rewording for clarity throughout. Coding, reference-table, background and references updated.	04/24	04/24
Semi-annual review. Updated title to reflect V1.205 version. NTRK Fusion Analysis Panel: Added all metastatic, progressive, advanced, inoperable, or unknown solid tumors to the criteria for testing and reworded the criteria to reflect a change in NCCN guidelines; Added cancer type for coverage (recurrent or metastatic vaginal cancer) based on NCCN guidelines; Added discussion and new NCCN and FDA references in the Background & References to support criteria changes; Updated NCCN version numbers in Background and Rationale and References. Tumor Specific ERBB2 (HER2) Deletion/Duplication (FISH and CISH): Added cancer types	11/24	11/24

Reviews, Revisions, and Approvals	Revision Date	Approval Date
for coverage (p53 abnormal endometrial carcinoma, Recurrent or metastatic vaginal cancer, Stage IIIB or higher muscle invasive bladder cancer, Metastatic small bowel adenocarcinoma) based on NCCN guidelines; Updated NCCN version numbers in Background and Rationale and References. Tumor Specific PD-L1 Protein Analysis: Added cancer type for coverage (recurrent or metastatic vaginal cancer) based on NCCN guidelines; Updated NCCN version numbers in Background and Rationale and References, added additional references to support coverage. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) FISH Panel Analysis: Updated NCCN version in Background and Rationale and references. Multiple Myeloma FISH Panel Analysis: Updated NCCN version in Background and Rationale and references. Tumor Specific PML/RARA Gene Rearrangement (Qualitative FISH and PCR): Updated NCCN version in Background and Rationale and References. Tumor Specific ALK Gene Rearrangement (Qualitative FISH and PCR) Tests: Updated NCCN version in Background and Rationale and References. Bladder Cancer Diagnostic and Recurrence FISH Tests: Coverage status changed from non-covered to covered based on LCD guidelines; Updated reference numbers in Policy Reference Table; Streamlined portions of Background and Rationale section for brevity; Updated References. Tumor Specific ROS1 Gene Rearrangement: Updated NCCN version in Background and Rationale and References. Tumor Specific FOLR1 Protein Analysis: Updated NCCN version in Background and Rationale and References. Tumor Specific RET Gene Rearrangement Tests (FISH): Added cancer types for coverage (Locally advanced, recurrent or metastatic esophageal or esophagogastric junction cancer, Locally advanced, recurrent or metastatic gastric cancer, Recurrent or metastatic vaginal cancer) based on NCCN guidelines; Updated NCCN version in Background and Rationale and References.		
Annual review. Minor rewording without clinical significance. Changed “investigational” statements to note “current evidence does not support” the test. Policy title change from Concert Genetics Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies to Concert Genetic Testing Oncology: Solid Tumor Molecular Diagnostics. Tumor-Type Agnostic Solid Tumor Molecular Profiling Panel Tests: Added clarifying criteria I.B.2 (and updated format of I.B) to better clarify coverage for unknown primary tumor types. Targeted RNA Fusion Panels for Solid Tumors: Added the phrase "performed on peripheral blood, bone marrow or solid tumors" in criterion II n order to match the wording in criterion I.; changed criteria name from "Targeted RNA Fusion Panels" to "Targeted RNA Fusion Panels for Solid Tumors"; removed "Adult or pediatric acute lymphoblastic leukemia (ALL)" from the indications for testing, and moved those indications to the hematologic malignancies policy. Tumor Specific ESR1 Variant Analysis: Updated criterion I.A to include term "sex assigned at birth" for clarity. Tumor Specific FOLR1 Protein Analysis: Removed criterion I.B (requiring that the drug Elahere is being considered for treatment in order to cover testing). Tumor Specific IDH1 and	11/25	12/25

Reviews, Revisions, and Approvals	Revision Date	Approval Date
IDH2 Variant Analysis (Solid Tumor): New criteria: criteria set was split is now solid-tumor specific and hematologic specific (hematologic cancers are addressed in Hematologic Molecular Diagnosis policy). Tumor Specific MGMT Methylation Analysis: Revised glioma criteria by condensing diagnosis requirements to 'high-grade (grade 3 or 4) glioma,' removing the detailed enumeration of specific glioma subtypes (e.g., anaplastic oligodendroglioma, astrocytoma, glioblastoma). Tumor Specific Microsatellite Instability (MSI) Analysis: Updated criteria language to include 'any of the following' in Criteria I.A. for clarity in diagnosis specification; added 'recurrent' to criteria I.A.9. to clarify coverage applies to recurrent unresectable or metastatic breast cancer. Tumor Specific PIK3CA Variant Analysis: Added the following coverage criteria: "The member has a distantly metastatic salivary gland tumor"; revised criteria A to include 'unresectable,' updating from the previous language of 'recurrent or stage IV, HR-positive, HER2-negative invasive breast cancer' to 'recurrent unresectable or stage IV, HR-positive, HER2-negative invasive breast cancer. Evidence-Based Solid Tumor Minimal Residual Disease (MRD) Testing: Added ovarian cancer to criterion I.D.2 as an indication for Signatera testing; changed "Metastatic breast cancer" to "Neoadjuvant breast cancer" in criterion I.D.2. Broad Molecular Profiling Panel Tests via Circulating Tumor DNA (ctDNA): updated lung cancer criteria to "metastatic" instead of "stage IV or metastatic" for clarity; updated criterion I.A.16 to add the word "neuroendocrine"; added criterion II (investigational criterion) for consistency with similar criteria sets. Lung Cancer Focused Panel Tests via Circulating Tumor DNA (ctDNA): Added the word "new" to criterion I.A., which now reads: "The member has a new diagnosis or progression of any of the following...". EGFR Variant Analysis via ctDNA: Removed criterion I.B (requirement for EGFR tyrosine kinase inhibitor therapy to be considered.) BRAF Variant Analysis via ctDNA: Removed criteria requiring that NRAS and KRAS testing be performed. KRAS Variant Analysis via ctDNA: Removed criteria requiring that NRAS and KRAS testing be performed; removed the following criteria, "Is being considered for anticancer therapy." Circulating Tumor Cell (CTC) Enumeration: clarified that the test is not supported by current evidence for all indications. Bladder Cancer Diagnostic and Recurrence FISH Tests: Removed criterion II "Bladder cancer diagnostic and recurrence FISH tests for screening of members with hematuria are considered investigational" because it was duplicative of Criterion I.A; updated criterion I.B.1.b (removed "per year") for clarity. Cancer Exome and Genome Sequencing: clarified that the test is not supported by current evidence for all indications. Added new criteria section: Broad RNA Fusion Panels for Solid Tumors. Policy reference table, rationale, background and coding table updated.		

REFERENCES

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2025.
https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 6.2024.
http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 6.2024.
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 3.2024.
https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1.2025.
https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
6. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Gastrointestinal Stromal Tumors (GISTs). Version 2.2024.
https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Central Nervous System Cancers. Version 3.2024.
https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2025.
https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
9. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 5.2024.
https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
10. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Occult Primary (Cancer of Unknown Primary [CUP]). Version 2.2025.
https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf
11. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Histiocytic Neoplasms. Version 3.2024
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf

12. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ampullary Adenocarcinoma. Version 2.2025.
https://www.nccn.org/professionals/physician_gls/pdf/ampullary.pdf
13. FoundationOne CDx Technical Information (PMA approval number: P170019). US Food and Drug Administration. Website:
https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019C.pdf. Accessed 08/12/2024.
14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Acute Lymphoblastic Leukemia. Version 3.2024.
https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
15. National Comprehensive Cancer Network. Biomarker Compendium.
<https://www.nccn.org/professionals/biomarkers/content/>. Accessed 11/6/2024.
16. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 4.2024.
https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf
17. Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion [published correction appears in J Clin Oncol. 2022 Jun 20;40(18):2068]. J Clin Oncol. 2022;40(11):1231-1258. doi:10.1200/JCO.21.02767
18. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 1.2025.
https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
19. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 1.2025.
https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
20. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 5.2024
https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf
21. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Hairy Cell Leukemia. Version 1.2025.
https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf
22. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancer. Version 5.2024.
https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
23. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Bowel Adenocarcinoma. Version 2.2025.
https://www.nccn.org/professionals/physician_gls/pdf/small_bowel.pdf
24. Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(11):1222-1245. doi:10.1200/JCO.19.02960

25. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Pediatric Acute Lymphoblastic Leukemia. Version 2.2025.
https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf
26. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Systemic Mastocytosis. Version 3.2024.
https://www.nccn.org/professionals/physician_gls/pdf/mastocytosis.pdf
27. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers. Version 6.2024.
https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf
28. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal. Version 1.2025.
https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf
29. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Uterine Neoplasms. Version 2.2025.
https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
30. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Version 1.2025.
https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf
31. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Vulvar Cancer. Version 4.2024.
https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf
32. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 1.2025.
https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf
33. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 2.2025.
https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
34. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 4.2024.
https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
35. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Vaginal Cancer. Version 3.2025.
https://www.nccn.org/professionals/physician_gls/pdf/vaginal.pdf
36. Merck & CO, Inc. KEYTRUDA (pembrolizumab). U.S. Food and Drug Administration. Website:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s071s090lbl.pdf.
Accessed 4/24/2024.

37. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Pediatric Central Nervous System Cancers. Version 2.2025.
https://www.nccn.org/professionals/physician_gls/pdf/ped_cns.pdf
38. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Local Coverage Determination. MolDX: Lab: Bladder/Urothelial Tumor Markers. (L33420). Available at: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33420>
39. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Billing and Coding Article. MolDX: Billing and Coding: Lab: Bladder/Urothelial Tumor Markers. (A53095). Available at: <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=53095&ver=25>
40. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 1.2025.
https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
41. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hepatocellular Carcinoma. Version 2.2024.
https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf
42. Bristol-Myers Squibb Company. Augtyro (repotrectinib). U.S. Food and Drug Administration. Website:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf Accessed 8/16/2024
43. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 6.2024.
https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
44. US Food and Drug Administration (FDA). Premarket Approval Document for PD-L1 IHC 22C3 pharmDx. (PMA Number: 150013. Supplement Number: S014). Available at: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013S014>
45. US Food and Drug Administration (FDA). Premarket Approval Document for PD-L1 IHC 22C3 pharmDx. (PMA Number: 150013. Supplement Number: S020). Available at: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013S020>
46. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Local Coverage Determination. MolDX: Minimal Residual Disease Testing for Cancer (L38779). Available at: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38779>
47. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58376). Available at: <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58376>

48. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321-346. doi:10.5858/arpa.2017-0388-CP
49. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Local Coverage Determination. MolDX: Phenotypic Biomarker Detection in Circulating Tumor Cells (L38566) Available at: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38566>

[back to top](#)

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable

legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of member/enrollees. This clinical policy is not intended to recommend treatment for member/enrollees. Member/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, member/enrollees, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, member/enrollees and their representatives agree to be bound by such terms and conditions by providing services to member/enrollees and/or submitting claims for payment for such services.

Note: For Medicaid member/enrollees, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.